<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21892977</article-id><article-id pub-id-type="pmc">3387647</article-id><article-id pub-id-type="publisher-id">cc8224</article-id><article-id pub-id-type="doi">10.1186/cc8224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Bench-to-bedside review: Vasopressin in the management of septic shock</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Russell</surname><given-names>James A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jrussell@mrl.ubc.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Critical Care Medicine, St Paul's Hospital, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6</aff><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>11</day><month>8</month><year>2011</year></pub-date><!-- PMC Release delay is 12 months and 0 days and was based on the epub date.--><pub-date pub-type="pmc-release"><day>11</day><month>8</month><year>2012</year></pub-date><volume>15</volume><issue>4</issue><fpage>226</fpage><lpage>226</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 BioMed Central Ltd</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/15/4/226"/><abstract><p>This review of vasopressin in septic shock differs from previous reviews by providing more information on the physiology and pathophysiology of vasopressin and vasopressin receptors, particularly because of recent interest in more specific AVPR1a agonists and new information from the Vasopressin and Septic Shock Trial (VASST), a randomized trial of vasopressin versus norepinephrine in septic shock. Relevant literature regarding vasopressin and other AVPR1a agonists was reviewed and synthesized. Vasopressin, a key stress hormone in response to hypotension, stimulates a family of receptors: AVPR1a, AVPR1b, AVPR2, oxytocin receptors and purinergic receptors. Rationales for use of vasopressin in septic shock are as follows: first, a deficiency of vasopressin in septic shock; second, low-dose vasopressin infusion improves blood pressure, decreases requirements for norepinephrine and improves renal function; and third, a recent randomized, controlled, concealed trial of vasopressin versus norepinephrine (VASST) suggests low-dose vasopressin may decrease mortality of less severe septic shock. Previous clinical studies of vasopressin in septic shock were small or not controlled. There was no difference in 28-day mortality between vasopressin-treated versus norepinephrine-treated patients (35% versus 39%, respectively) in VASST. There was potential benefit in the prospectively defined stratum of patients with less severe septic shock (5 to 14 &#x003bc;g/minute norepinephrine at randomization): vasopressin may have lowered mortality compared with norepinephrine (26% versus 36%, respectively, <italic>P </italic>= 0.04 within stratum). The result was robust: vasopressin also decreased mortality (compared with norepinephrine) if less severe septic shock was defined by the lowest quartile of arterial lactate or by use of one (versus more than one) vasopressor at baseline. Other investigators found greater hemodynamic effects of higher dose of vasopressin (0.06 units/minute) but also unique adverse effects (elevated liver enzymes and serum bilirubin). Use of higher dose vasopressin requires further evaluation of efficacy and safety. There are very few studies of interactions of therapies in critical care - or septic shock - and effects on mortality. Therefore, the interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock was evaluated in VASST. Low-dose vasopressin infusion plus corticosteroids significantly decreased 28-day mortality compared with corticosteroids plus norepinephrine (44% versus 35%, respectively, <italic>P </italic>= 0.03; <italic>P </italic>= 0.008 interaction statistic). Prospective randomized controlled trials would be necessary to confirm this interesting interaction. In conclusion, low-dose vasopressin may be effective in patients who have less severe septic shock already receiving norepinephrine (such as patients with modest norepinephrine infusion (5 to 15 &#x003bc;g/minute) or low serum lactate levels). The interaction of vasopressin infusion and corticosteroid treatment in septic shock requires further study.</p></abstract></article-meta></front><body><sec><title>Vasopressin receptors</title><p>Vasopressin stimulates a family of receptors: AVPR1a (also known as V1 receptor, mainly vascular), AVPR1b (V3 receptor, mainly central), AVPR2 (V2 receptor, mainly renal), oxytocin receptors and purinergic receptors. AVPR1a, a G-protein coupled receptor, is responsible for vasoconstriction associated with vasopressin and is expressed on vascular smooth muscle, hepatocytes and platelets (Figure <xref ref-type="fig" rid="F1">1</xref>). G proteins stimulate a phosphatidyl-inositol-calcium signaling pathway, causing smooth muscle contraction [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Stimulation of the AVPR1a receptor also induces production of the potent vasodilator nitric oxide in coronary vessels [<xref ref-type="bibr" rid="B4">4</xref>] and pulmonary vessels [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Genetic variants of AVPR1a have been associated with essential hypertension [<xref ref-type="bibr" rid="B2">2</xref>], autism [<xref ref-type="bibr" rid="B8">8</xref>], and generosity [<xref ref-type="bibr" rid="B9">9</xref>]. The effects of sepsis on AVPR1a are complex and include downregulation of the receptor [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>], yet there can be increased sensitivity to vasopressin in sepsis (compared with normal controls who are hemodynamically stable) [<xref ref-type="bibr" rid="B12">12</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Vasopressin occupies the AVPR1a receptor</bold>. Vasopressin (line and beads) occupies the AVPR1a receptor.</p></caption><graphic xlink:href="cc8224-1"/></fig><p>AVPR1b (or V3 receptor) is expressed in the anterior pituitary gland and hippocampus. Stimulation of AVPR1b by vasopressin releases adrenocorticotropic hormone (ACTH) because vasopressin flows from the posterior pituitary through pituitary portal capillaries to bind to the AVPR1b on corticotrophic cells of the anterior pituitary. Vasopressin thus interacts with the corticosteroid axis in response to stresses such as hypotension [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Vasopressin and corticotrophin-releasing hormone stimulate different signaling systems and have synergistic effects on release of ACTH. AVPR1b knockout mice have an impaired stress response because of blunted ACTH response [<xref ref-type="bibr" rid="B15">15</xref>]. In contrast, overexpression of AVPR1b has been associated with pituitary adenomas and ectopic ACTH syndrome [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>AVPR2 (V2 receptor) is expressed in the renal collecting duct. Vasopressin is a trophic factor of the ascending limb of Henle and thereby creates the gradient that mediates vasopressin's antidiuretic effect. AVPR2 stimulation increases retention of water (antidiuretic activity) by increasing cyclic AMP, which causes movement of aquaporin-2 water channels from cytoplasm to the apical membrane of collecting duct cells. If there is vasopressin deficiency, aquaporin-2 channels internalize from the apical membrane to subapical vesicles so that there is no active water reabsorption. Absence of vasopressin also results in decreased synthesis of aquaporin-2, further impairing water reabsorption. The V2 receptor also mediates vasodilation by stimulating the nitric oxide pathway [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>].</p><p>Over 150 mutations of the AVPR2 receptor have been reported associated with nephrogenic diabetes insipidus. Stimulation of the AVPR2 receptor increases release of von Willebrand factor, von Willebrand factor multimers, and risk of clotting. Stimulation of AVPR2 is therefore the mechanism for increased coagulation in response to desmopressin. Interestingly, von Willebrand factor levels are increased in sepsis [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Sepsis may downregulate vasopressin receptors. Expression of AVPR1a is downregulated in studies of models of sepsis, thereby limiting smooth muscle contraction and increase of blood pressure [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B21">21</xref>], AVPR2 receptors [<xref ref-type="bibr" rid="B22">22</xref>] and AVPR3 receptors [<xref ref-type="bibr" rid="B23">23</xref>]. Downregulation AVPR1a in the lung, liver, kidney and heart is probably caused by increased TNF&#x003b1;, IL-1&#x003b2;, IL-6 and IFN&#x003b3; [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. The magnitude of downregulation of AVPR1a may be large because continuous infusion of lipopolysaccharide decreased AVPR1A expression by 43% [<xref ref-type="bibr" rid="B11">11</xref>]. Models of sepsis also downregulate AVPR1b and AVPR2. Lipopoly-saccharide decreases mRNA levels of the AVPR1b receptor in the pituitary [<xref ref-type="bibr" rid="B23">23</xref>] and downregulates AVPR2 expression in rat renal medulla [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>Vasopressin also simulates oxytocin receptors to cause vasodilation [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Stimulation of oxytocin receptors increases nitric oxide and thus causes vasodilation [<xref ref-type="bibr" rid="B26">26</xref>]. Stimulation of oxytocin receptors also increases release of atrial natriuretic peptide [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. The oxytocin receptor is downregulated in the heart in response to ischemia- reperfusion injury; this downregulation of the receptor may explain the potentially detrimental effects of vasopressin in myocardial ischemia-reperfusion, including increased mortality and decreased myocardial contractility [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Purinergic receptors are also stimulated by vasopressin [<xref ref-type="bibr" rid="B27">27</xref>]. At low doses, vasopressin acts on purinergic receptors that mediate endothelial vasodilation; this effect is reversed when high-dose vasopressin stimulates the AVPR1a receptor to mediate vasoconstriction.</p><p>The vasopressin neurons of the hypothalamus and neurohypophysis are innervated by a variety of pathways that carry information regarding, firstly, blood volume/blood pressure and, secondly, osmolality. Purinergic receptors are also important components of the stimulation of release of vasopressin. ATP is a neurotransmitter that signals through the purinergic P2 receptors (P2X2 [<xref ref-type="bibr" rid="B28">28</xref>], P2X3 [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>] and P2Y1 [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]) to increase cytosolic free calcium [<xref ref-type="bibr" rid="B33">33</xref>], which then stimulates release of vasopressin from the neurohypophysis [<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B37">37</xref>]. The P2X5 receptor is expressed and co-localized with vasopressin on paraventricular and supraoptic nuclei of the hypo-thalamus, suggesting that P2X5 is also important in the stimulation of vasopressin release [<xref ref-type="bibr" rid="B38">38</xref>]. The stimulatory effects of ATP on vasopressin release are synergized (that is, an increased amount and duration of vasopressin release) by co-stimulation with norepinephrine [<xref ref-type="bibr" rid="B39">39</xref>] acting as neurotransmitters via P2X [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>] and P2Y1 [<xref ref-type="bibr" rid="B41">41</xref>] receptors. This synergistic action of ATP and nor-epinephrine in the neurohypophysis may be important for the sustained release of vasopressin during hypotension [<xref ref-type="bibr" rid="B36">36</xref>]. The stimulation of vasopressin release by ATP is terminated by adenosine, a metabolite of ATP, and is thus a natural negative feedback mechanism of vasopressin release [<xref ref-type="bibr" rid="B42">42</xref>].</p><p>ATP also stimulates P2Y1 and P2Y2 receptors of the convoluted tubule of the nephron to modulate vasopressin antidiuretic effects [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Indeed, P2Y2 knock-out mice have salt-resistant hypertension [<xref ref-type="bibr" rid="B45">45</xref>]. Further-more, the cardiac effects of vasopressin are mediated at least in part through P2X and P2Y receptors [<xref ref-type="bibr" rid="B46">46</xref>].</p></sec><sec><title>Synthesis, release and clearance of vasopressin</title><p>Vasopressin is synthesized and released into the systemic circulation from the posterior pituitary gland (Figure <xref ref-type="fig" rid="F2">2</xref>). Vasopressin, like many hormones, is synthesized as a prohormone and then is cleaved to form the mature active hormone. Serum levels of vasopressin - a nonapeptide - represent the interactions of the synthesis, release, and metabolism of vasopressin. Synthesis of preprovasopressin occurs in neurophypophyseal neurons (also known as magnocellular neurons) of paraventricular and supraoptic nuclei of the hypothalamus. Provasopressin is packaged in neurosecretory granules and transported along the suprahypophyseal tract to the posterior pituitary. Subsequently, there is conversion to provasopressin followed by conversion of provasopressin by subtilisin-like proprotein convertase (SPC3) to vasopressin.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>The hypothalamic pituitary axis and vasopressin</bold>. Provasopressin is synthesized in neurohypophyseal neurons of the paraventricular nuclei (PVN) and supraoptic nuclei (SON) of the hypothalamus. Provasopressin is transported along the supraoptic neurohypophyseal tract in neurosecretory granules to the posterior pituitary gland. Provasopressin is cleaved by enzymes to vasopressin during transport to the posterior pituitary gland. Hypotension and hyperosmolality stimulate release of stored vasopressin (immediate) and synthesis (delayed) of vasopressin. In response to hypotension, vasopressin is released into the systemic circulation and also into the pituitary portal capillaries, flows to the anterior pituitary, binds to the AVPR1b receptor of corticotrophs, and stimulates release of adrenocorticotropic hormone. MNPO, median pre-optic nucleus.</p></caption><graphic xlink:href="cc8224-2"/></fig><p>Vasopressin is metabolized by several promiscuous vasopressinases such as LNPEP and IRAP. LNPEP metabolizes vasopressin and also clears oxytocin (a vasodilator), GLUT4 (which modulates cellular uptake of glucose) and angiotensin-converting enzyme 4 (which converts angiotensinogen to the potent vasoconstrictor angiotensin), indicating that variations in levels and function of LNPEP could have complex effects on hemodynamics and blood pressure in sepsis.</p><p>Sepsis initially increases vasopressin levels by 20-fold to 200-fold to supraphysiologic levels by several mechanisms. Early studies by Wilson and colleagues in endotoxin-induced shock and <italic>Escherichia coli</italic>-induced shock found that vasopressin levels were &#x0003e;500 pg/ml in dogs and &#x0003e;300 pg/ml in baboons within 15 minutes of initiation of sepsis [<xref ref-type="bibr" rid="B47">47</xref>]. This increase of vasopressin levels occurred when cardiac output was decreased but before hypotension, suggesting that stimuli other than hypotension - such as increased levels of mediators of inflammation and decreased cardiac output - stimulated the increase of vasopressin levels. Furthermore, endotoxin stimulates the release of vasopressin into hypophyseal portal blood. Hypotension and hypernatremia stimulate release of stored vasopressin (immediate) and synthesis of vasopressin (delayed). Vasopressin stores are thus ample and available for instantaneous release from the posterior pituitary in response to sepsis, septic shock and hypotension.</p><p>Vasopressin levels increase early in septic shock because hypotension is the most potent stimulus for release and synthesis of vasopressin. Indeed, if an animal is challenged with conflicting signals to vasopressin release (such as hypotension and hyponatremia), the animal will increase vasopressin. After the initial release of vasopressin, which increases vasopressin levels in septic shock, vasopressin levels then decline rapidly - because of depletion of stored vasopressin - to levels that are inappropriately low (compared with similarly hypotensive patients who have cardiogenic shock [<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]). The decrease in vasopressin levels is initially due to the depletion of vasopressin in the post-hypophyseal centers, but vasopressin levels remain extremely, inappropriately low [<xref ref-type="bibr" rid="B50">50</xref>,<xref ref-type="bibr" rid="B51">51</xref>], suggesting that there is also a sustained impairment of synthesis and release of vasopressin. Indeed, consistent with these earlier studies, vasopressin levels remained extremely low for up to 7 days after onset of septic shock in the Vasopressin and Septic Shock Trial (VASST) (Figure <xref ref-type="fig" rid="F3">3</xref>) [<xref ref-type="bibr" rid="B52">52</xref>]. Few endocrine systems are so rapidly activated (to increase serum levels) and then are so rapidly exhausted (such that serum levels decrease) as the vasopressin axis in sepsis.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Plasma vasopressin levels in the Vasopressin and Septic Shock Trial</bold>. Plasma vasopressin levels in patients in the Vasopressin and Septic Shock Trial who were infused with vasopressin compared with norepinephrine. Plasma vasopressin levels over time in patients receiving a vasopressin infusion (<italic>n </italic>= 54, black squares), patients in the vasopressin group once vasopressin infusions had stopped (open squares), and patients in the norepinephrine group (<italic>n </italic>= 53, grey circles). Values are median and interquartile range (IQR).</p></caption><graphic xlink:href="cc8224-3"/></fig><p>Ironically, even though vasopressin levels fall to very low levels in septic shock, some evidence suggests that low plasma levels of vasopressin may not be associated with increased mortality. A recent study found that plasma levels of provasopressin were significantly higher in nonsurvivors of septic shock (Table <xref ref-type="table" rid="T1">1</xref>) [<xref ref-type="bibr" rid="B53">53</xref>]. Therefore, it is intriguing to speculate that this lack of association of vasopressin levels and mortality could be interpreted to indicate that the decrease of vasopressin levels could be adaptive. The studies of levels of vasopressin and outcome must also be interpreted with an understanding of when vasopressin levels were measured during the course of illness, because changing levels of vasopressin (increased early and decreased later) could be linked to outcomes.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Vasopressin and copeptin levels in humans</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Condition</th><th align="center">Vasopressin (AVP) levels</th><th align="center">Provasopressin</th><th align="center">Copeptin levels</th></tr></thead><tbody><tr><td align="left"><bold>Landry and colleagues </bold>[<xref ref-type="bibr" rid="B48">48</xref>]</td><td align="left"><bold>Septic shock</bold></td><td align="center"><bold>3.1 pg/ml</bold></td><td/><td/></tr><tr><td/><td align="left">Cardiogenic shock</td><td align="center">22.7 pg/ml</td><td/><td/></tr><tr><td align="left"><bold>Lin and colleagues </bold>[<xref ref-type="bibr" rid="B61">61</xref>]</td><td align="left"><bold>Septic shock</bold></td><td align="center"><bold>3.6 pg/ml</bold></td><td/><td/></tr><tr><td/><td align="left">Sepsis</td><td align="center">10.6 pg/ml</td><td/><td/></tr><tr><td/><td align="left">Severe sepsis</td><td align="center">21.8 pg/ml</td><td/><td/></tr><tr><td align="left">Jochberger and colleagues [<xref ref-type="bibr" rid="B59">59</xref>]</td><td align="left">Sepsis</td><td align="center">11.9 pg/ml</td><td/><td/></tr><tr><td align="left"><bold>Morgenthaler and colleagues </bold>[<xref ref-type="bibr" rid="B57">57</xref>]</td><td align="left">Critically ill (no sepsis)</td><td/><td/><td align="center">27 pM</td></tr><tr><td/><td align="left">Sepsis</td><td/><td/><td align="center">50 pM</td></tr><tr><td/><td align="left">Severe sepsis</td><td/><td/><td align="center">74 pM</td></tr><tr><td/><td align="left"><bold>Septic shock</bold></td><td/><td/><td align="center"><bold>171 pM</bold></td></tr><tr><td align="left"><bold>Lodha and colleagues </bold>[<xref ref-type="bibr" rid="B64">64</xref>]</td><td align="left"><bold>Pediatric septic shock</bold></td><td align="center"><bold>116 pg/ml</bold></td><td/><td/></tr><tr><td/><td align="left">Pediatric severe sepsis</td><td align="center">106 pg/ml</td><td/><td/></tr><tr><td/><td align="left">Multiple trauma</td><td align="center">44.3 pM</td><td/><td/></tr><tr><td align="left"><bold>Russell and colleagues </bold>[<xref ref-type="bibr" rid="B52">52</xref>]</td><td align="left"><bold>Septic shock</bold></td><td align="center"><bold>3.2 pM</bold></td><td/><td/></tr><tr><td/><td align="left">Septic shock plus vasopressin infusion (0.03 U/minute) at 6 hours</td><td align="center">74 pM</td><td/><td/></tr><tr><td/><td align="left">Septic shock plus vasopressin infusion (0.03 U/minute) at 24 hours</td><td align="center">98 pM</td><td/><td/></tr><tr><td align="left"><bold>Jochberger and colleagues </bold>[<xref ref-type="bibr" rid="B53">53</xref>]</td><td align="left">Infection</td><td align="center">3.2 pM*</td><td/><td align="center">25 pM*</td></tr><tr><td/><td align="left">Severe sepsis</td><td align="center">6.5 pM*</td><td/><td align="center">60 pM*</td></tr><tr><td/><td align="left"><bold>Septic shock</bold></td><td align="center"><bold>6.4 pM*</bold></td><td/><td align="center"><bold>70 pM*</bold></td></tr><tr><td align="left"><bold>Sharshar and colleagues</bold>[<xref ref-type="bibr" rid="B138">138</xref>]</td><td align="left"><bold>Septic shock</bold></td><td align="center"><bold>1.6, 1.8, 16 pg/ml</bold></td><td/><td/></tr><tr><td/><td/><td align="center"><bold>Low neurophypophyseal T1 (AVP)</bold></td><td/><td/></tr><tr><td/><td align="left"><bold>Neurohypophyseal levels of AVP</bold></td><td/><td/><td/></tr><tr><td align="left"><bold>Sharshar and colleagues </bold>[<xref ref-type="bibr" rid="B139">139</xref>]</td><td align="left"><bold>Septic shock</bold></td><td align="center"><bold>X</bold></td><td/><td/></tr><tr><td align="left"><bold>Le Clerc and colleagues </bold>[<xref ref-type="bibr" rid="B140">140</xref>]</td><td align="left"><bold>Pediatric meningococcal shock</bold></td><td align="center"><bold>X</bold></td><td/><td/></tr><tr><td align="left">Kruger and colleagues [<xref ref-type="bibr" rid="B141">141</xref>]</td><td align="left">Community-acquired pneumonia</td><td/><td/><td/></tr><tr><td/><td align="left">Antibiotic pretreatment</td><td/><td/><td align="center">12.8 pmol/l</td></tr><tr><td/><td align="left">Community-acquired pneumonia</td><td/><td/><td/></tr><tr><td/><td align="left">No antibiotic pretreatment</td><td/><td/><td align="center">20. 8 pmol/l</td></tr><tr><td align="left"><bold>de Kruif and colleagues </bold>[<xref ref-type="bibr" rid="B142">142</xref>]</td><td align="left"><bold>Pre <italic>Escherichia coli </italic>endotoxin in humans</bold></td><td/><td align="center"><bold>12.5 pmol/l</bold></td><td/></tr><tr><td/><td align="left"><bold>Peak <italic>E. coli </italic>endotoxin in humans</bold></td><td/><td align="center"><bold>18.0 pmol/l</bold></td><td/></tr><tr><td/><td align="left"><bold>Prednisone 10 mg pretreatment. Peak <italic>E. coli </italic>endotoxin in humans</bold></td><td/><td align="center"><bold>10.6 pmol/l</bold></td><td/></tr><tr><td/><td align="left"><bold>Prednisone 30 mg pretreatment. Peak <italic>E. coli </italic>endotoxin in humans</bold></td><td/><td align="center"><bold>6.1pmol/l</bold></td><td/></tr></tbody></table><table-wrap-foot><p>*Estimated from the figures and text of Jochberger and colleagues [<xref ref-type="bibr" rid="B53">53</xref>]. Studies of septic shock are in bold for comparison.</p></table-wrap-foot></table-wrap><p>The discussion of appropriate levels of vasopressin in septic shock leads logically to the following fundamental question regarding the design of vasopressin intervention studies. Should vasopressin be infused as very-low-dose replacement therapy (opotherapy), at higher doses for vasopressin's vasoconstrictive properties, or at supra-physiologic levels? At low plasma levels of vasopressin (&#x0003c;10 pmol/l), vasopressin's V2 receptor antidiuretic actions predominate. At higher levels, the vasoconstrictive properties of vasopressin are initiated and become progressively predominant. There is also, however, vasodilation caused by vasopressin (caused by vasopressin's stimulation of AVPR1a, AVPR1b, and oxytocin receptors).</p><p>The early increase in vasopressin release in septic shock is modulated by inducible nitric oxide synthase-induced increase of nitric oxide [<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. Heme-oxygenase activation in sepsis attenuates the increase of AVP in septic shock [<xref ref-type="bibr" rid="B56">56</xref>].</p><p>Copeptin, a 39-amino-acid glycopeptide, is the C terminal of provasopressin (similar to the C peptide of insulin [<xref ref-type="bibr" rid="B6">6</xref>]) and is stable in plasma, and is therefore easier to measure than vasopressin. Some studies have therefore suggested that copeptin could be used as a surrogate for measurement of vasopressin [<xref ref-type="bibr" rid="B57">57</xref>-<xref ref-type="bibr" rid="B60">60</xref>]. Landry and colleagues first discovered that vasopressin levels are inappropriately low in septic shock [<xref ref-type="bibr" rid="B45">45</xref>,<xref ref-type="bibr" rid="B49">49</xref>] (Table <xref ref-type="table" rid="T1">1</xref>). Other workers found that vasopressin levels were lower in emergency patients who progressed to septic shock (3.6 pg/ml) compared with patients who had sepsis (10.6 pg/ml) and severe sepsis (21.8 pg/ml) [<xref ref-type="bibr" rid="B61">61</xref>].</p><p>Critically ill patients have higher copeptin levels than normal volunteers [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B60">60</xref>,<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>]. Morgenthaler and colleagues found increased copeptin levels in human sepsis and septic shock (means: normal volunteers, 4 pM; critically ill patients, no sepsis, 27 pM; sepsis patients, 50 pM; severe sepsis patients, 74 pM; septic shock patients, 171 pM) [<xref ref-type="bibr" rid="B57">57</xref>]. Furthermore, patients who had hemodynamic dysfunction had higher vasopressin levels (and copeptin levels) than patients without hemodynamic dysfunction (AVP, 14.1 pg/ml versus 8.7 pg/ml). Patients who are post cardiovascular surgery usually have higher vasopressin and copeptin levels than patients with septic shock [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B60">60</xref>]. Copeptin was higher in nonsurvivors (versus survivors) in at least two studies of adult septic shock (171 pM versus 87 pM [<xref ref-type="bibr" rid="B57">57</xref>] and 70 pM versus 24 pM [<xref ref-type="bibr" rid="B58">58</xref>]) and in one study of pediatric septic shock [<xref ref-type="bibr" rid="B64">64</xref>]. Lodha and colleagues [<xref ref-type="bibr" rid="B64">64</xref>] found that serum vasopressin levels in pediatric septic shock are similar to the results of Jochberger and colleagues [<xref ref-type="bibr" rid="B53">53</xref>]. Vasopressin levels were increased in septic shock (116 pg/ml) and severe sepsis (106 pg/ml), and vasopressin levels did not change over 96 hours.</p><p>Do serum levels of copeptin and vasopressin correlate tightly, such that copeptin is a surrogate for vasopressin? I suggest copeptin levels should not be used as a surrogate for vasopressin levels at this time without further evaluation.</p><p>There are fascinating interactions of vasopressin with the baroreceptor reflex and neural control of the cardiovascular system. It is well known that vasopressin infusion causes bradycardia in normal animals and humans because of stimulation of the baroreceptor reflex by vasopressin. In addition, infused vasopressin also enters the brain and modulates the sensitivity of the baroreceptor reflex. Vasopressin is also an important neurotransmitter in the brain that regulates the brain-stem control of the cardiovascular system. Vasopressin is also a key regulator of the behavioral response to stress.</p></sec><sec><title>Effects of infused vasopressin in septic shock</title><p>Vasopressin infusion increases vasopressin levels rapidly [<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. The effects of vasopressin infusion on copeptin levels are not known. Responses to vasopressin and norepinephrine, however, are modified in sepsis. One fundamental concept shown repeatedly in animal studies of sepsis is that the effects of vasopressin (both beneficial and adverse) in models of sepsis depend critically on the volume status of the animal [<xref ref-type="bibr" rid="B65">65</xref>]. For example, volume loading in models of sepsis is critical to minimizing and ameliorating the adverse mesenteric vasoconstriction that can produce intestinal ischemia [<xref ref-type="bibr" rid="B12">12</xref>]. These observations highlight the central importance of adequate volume resuscitation of patients before infusion of vasopressin is considered.</p><p>Fecal peritonitis was used to evaluate the vascular effects on mesenteric artery vasoconstriction in response to norepinephrine, vasopressin, and a selective AVPR1a agonist (F180) [<xref ref-type="bibr" rid="B12">12</xref>]. The vasoconstrictor responses to vasopressin and the AVPR1a agonist were enhanced whereas responses to norepinephrine were severely impaired. There thus appeared to be vasopressin hyper-sensitivity in the mesenteric circulation.</p><p>Nakajima and colleagues evaluated vasopressin, nor-epinephrine, and L-arginine effects on intestinal circulation in a septic shock model [<xref ref-type="bibr" rid="B66">66</xref>]. Lipopolysaccharide decreased perfused intestinal villi flow; and vasopressors increased the mean arterial pressure (MAP) and prevented further falls in perfused intestinal villi. Knotzer and colleagues studied vasopressin in an acute endotoxin model of septic shock and found decreased jejunal oxygenation [<xref ref-type="bibr" rid="B67">67</xref>]. There was no effect (that is, no further worsening) from vasopressin.</p><p>In contrast, other studies have found decreased vascular responsiveness to vasopressin in models of septic shock [<xref ref-type="bibr" rid="B68">68</xref>]. There was a synergistic effect of vasopressin and norepinephrine on vascular responsiveness.</p><p>The effects of vasopressin differed in several vascular beds in sepsis [<xref ref-type="bibr" rid="B69">69</xref>,<xref ref-type="bibr" rid="B70">70</xref>]. Renal blood flow was lower with norepinephrine than vasopressin; hepatic blood flow was lower with vasopressin than norepinephrine, while coronary blood flow was similar with vasopressin and norepinephrine.</p><p>Patients who have septic shock have decreased forearm vascular resistance, as a component of decreased systemic vascular resistance. The forearm vasoconstrictor response to phenylephrine (&#x003b1;-agonist) and angiotensin II was impaired whereas the response to vasopressin was enhanced in septic shock compared with normal [<xref ref-type="bibr" rid="B71">71</xref>].</p><p>There have been many small studies of the effects of vasopressin infusion reviewed recently [<xref ref-type="bibr" rid="B72">72</xref>]. Vasopressin infusion decreases the dose requirement of norepinephrine, increases urine output and creatinine clearance, and sometimes decreases cardiac output [<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B73">73</xref>-<xref ref-type="bibr" rid="B78">78</xref>]. These studies, however, were not powered for the 28-day mortality rate or organ dysfunction.</p><p>The side effects of vasopressin studied in animal models of septic shock are conflicting because of differences in models (acute, type of septic insult, chronic), doses of vasopressin, and duration of studies (hours versus days). For example, vasopressin infusion (0.06 units/kg/hour) increased the MAP but also decreased mesenteric blood flow by one-half and decreased microcirculatory flow to gastric mucosa (by 23%) and to jejunal mucosa (by 27%) in porcine fecal peritonitis [<xref ref-type="bibr" rid="B79">79</xref>].</p><p>Adverse effects of vasopressin reported in studies of humans include mesenteric ischemia, myocardial ischemia, digital ischemia, skin necrosis, and hyponatremia, to name a few [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B67">67</xref>,<xref ref-type="bibr" rid="B76">76</xref>,<xref ref-type="bibr" rid="B78">78</xref>,<xref ref-type="bibr" rid="B80">80</xref>]. These studies were small, nonblinded, and often uncontrolled, however, so the true risks of low-dose vasopressin infusion in septic shock are unknown. Vasopressin has complex effects on the immune and inflammatory responses. Ironically, commonly used catecholamines (epinephrine and, to a lesser extent, norepinephrine) induce an inflammatory response in hepatocytes [<xref ref-type="bibr" rid="B81">81</xref>] similar to lipopolysaccharide. Effects such as these could be harmful directly or indirectly in patients who have septic shock.</p><p>The effects of infused vasopressin on endogenous vasopressin synthesis and release are not known. Early withdrawal of vasopressin infusion in septic shock can lead to a rapid drop in vasopressin levels (Figure <xref ref-type="fig" rid="F3">3</xref>), sometimes to such low levels of vasopressin that hemodynamic instability could recur. The risk of vasopressin deficiency after withdrawal of vasopressin infusion may be increased in patients who are also on corticosteroids because corticosteroids inhibit vasopressin secretion.</p></sec><sec><title>The Vasopressin and Septic Shock Trial</title><p>VASST, a randomized controlled trial of vasopressin versus norepinephrine in patients with septic shock, was performed to address uncertainties regarding vasopressin in septic shock [<xref ref-type="bibr" rid="B52">52</xref>]. The primary hypothesis was that vasopressin, compared with norepinephrine infusion, would decrease 28-day mortality from 60% to 50%. An important secondary hypothesis was that the effects of vasopressin, compared with norepinephrine, would be more pronounced in patients with more severe septic shock. We therefore stratified patients into less and more severe septic shock.</p><p>We studied adults with septic shock on norepinephrine treatment. Septic shock was defined by infection, two or more of the systemic inflammatory response syndrome criteria [<xref ref-type="bibr" rid="B82">82</xref>], at least one new dysfunction, and vasopressor support (5 &#x003bc;g/minute norepinephrine (or equivalent) for 6 hours). Exclusion criteria are listed in the online supplement [<xref ref-type="bibr" rid="B52">52</xref>]. It should be noted that the MAP of patients at baseline in VASST was 72 mmHg, suggesting to some that the patients may not have been in septic shock. All patients were on at least 5 &#x003bc;g/minute norepinephrine (or equivalent), however, which satisfies the commonly used definitions of septic shock [<xref ref-type="bibr" rid="B83">83</xref>-<xref ref-type="bibr" rid="B86">86</xref>].</p><p>The study drugs were vasopressin or norepinephrine; stratification variables were the center and severity of shock. Less severe septic shock was defined as infusion of 5 to 14 &#x003bc;g/minute norepinephrine (or equivalent) while more severe septic shock was defined as &#x02265;15 &#x003bc;g/minute norepinephrine (or equivalent) in the hour before randomization. Blinded vasopressin infusion was titrated from 0.01 U/minute to 0.03 U/minute, while blinded norepinephrine infusion was titrated from 5 &#x003bc;g/minute to 15 &#x003bc;g/minute. Clinicians titrated open-label vasopressors to maintain a MAP of 65 to 75 mmHg. Weaning of open-label vasopressors occurred when the goal MAP had been achieved during study drug infusion. The study drug was weaned when MAP was maintained for 8 hours without open-label vasopressors. Infusion of the study drug was continued until the patient died, had a serious adverse event, or stabilized so that open-label vasopressors were no longer needed.</p><p>Patients enrolled in VASST were severely ill (for example, high Acute Physiology and Chronic Health Evaluation II scores, high fraction with new organ dysfunction, high norepinephrine infusion rates). The MAP was similar in the two treatment groups (Figure <xref ref-type="fig" rid="F4">4a</xref>). The heart rate was significantly lower in the vasopressin group than in the norepinephrine group (first 4 days) (Figure <xref ref-type="fig" rid="F4">4b</xref>). As in previous human studies, vasopressin infusion allowed a rapid decrease of the norepinephrine dose (over the first 4 days) (Figure <xref ref-type="fig" rid="F5">5</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Mean arterial pressure and heart rate in the Vasopressin and Septic Shock Trial</bold>. Comparison of <bold>(a) </bold>mean arterial pressure (MAP) and <bold>(b) </bold>heart rate in the norepinephrine group (grey circles) and in the vasopressin group (black squares) of the Vasopressin and Septic Shock Trial. Values are mean &#x000b1; standard deviation (SD). Heart rate was significantly lower in the vasopressin group than in the norepinephrine group over the first 4 days (<italic>P </italic>&#x0003c; 0.001). There were no statistically significant differences between the norepinephrine and vasopressin groups in MAP.</p></caption><graphic xlink:href="cc8224-4"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Doses of norepinephrine infusions in the Vasopressin and Septic Shock Trial</bold>. Rates of total norepinephrine infusion (open-label and study drug) in the Vasopressin and Septic Shock Trial for the vasopressin-treated group (black squares) and for the norepinephrine-treated group (grey circles) amongst all patients who were treated with open-label norepinephrine at baseline. The rates of norepinephrine infusion were significantly lower in the vasopressin group than in the norepinephrine group over the first 4 days (<italic>P </italic>&#x0003c; 0.001). Values are median and interquartile range (IQR).</p></caption><graphic xlink:href="cc8224-5"/></fig><p>Plasma vasopressin was extremely low at baseline (median 3.2 pmol/l) and did not change in the norepinephrine group. Low-dose vasopressin infusion increased vasopressin levels to 73.6 pmol/l (median at 6 hours) and 98.0 pmol/l (24 hours) (Figure <xref ref-type="fig" rid="F3">3</xref>). These levels of vasopressin may be supraphysiological because those levels of vasopressin are rarely observed in the very acute phase of septic shock. Some studies found that vasopressin levels increased 200-fold, however, suggesting the circulating levels of vasopressin in VASST were not supraphysiologic.</p><p>There was no significant difference between vasopressin-treated and norepinephrine-treated groups in 28-day mortality (35.4% versus 39.3%, <italic>P </italic>= 0.26; absolute risk reduction (ARR) = -2.9 to 10.7%), in 90-day mortality (43.9% versus 49.6%, respectively, <italic>P </italic>= 0.11; ARR = -1.3 to 12.8%), or in organ dysfunction rates (Figure <xref ref-type="fig" rid="F6">6</xref>). VASST was prospectively powered to detect an absolute difference in mortality of 10% from an expected 60%. Interestingly, the overall mortality rate was considerably lower (37%) in VASST than previously reported.</p><fig id="F6" position="float"><label>Figure 6</label><caption><p><bold>Survival curve for Vasopressin and Septic Shock Trial vasopressin-infused patients compared with norepinephrine-infused patients</bold>. Ninety-day Kaplan-Meier survival curves for all randomized and infused patients (<italic>P </italic>= 0.27 at day 28; <italic>P </italic>= 0.10 at day 90). Solid line, vasopressin-infused group; dotted line, norepinephrine-infused group. <italic>P </italic>values were calculated using the log-rank statistic.</p></caption><graphic xlink:href="cc8224-6"/></fig><p>Vasopressin may have decreased mortality in patients who had less severe septic shock in VASST. At baseline, patients who had less severe septic shock had lower Acute Physiology and Chronic Health Evaluation II score, higher arterial pressure, lower lactate, lower norepinephrine dose, and a lower proportion presenting organ dysfunction than patients who had more severe septic shock. There were trends suggesting an association of vasopressin infusion with decreased 28-day (and 90-day) mortality in less severe septic shock. <italic>Post hoc </italic>analyses stratified by indicators of severity of shock suggested a possible advantage of vasopressin. Stratification by lactate quartile and by number of vasopressors at baseline was significant. In distinct contrast, there were no differences in mortality in more severe septic shock between vasopressin and norepinephrine. The test for the interaction of treatment group by severity of shock subgroup, however, was not significant (<italic>P </italic>= 0.10).</p><p>The potential benefits of vasopressin (compared with norepinephrine) in patients who had less severe septic shock were somewhat delayed so might not have been directly related to rapid reversal of septic shock. Kaplan-Meier curves show that the vasopressin-treated patients separated from the norepinephrine-treated patients at about day 10 (Figure <xref ref-type="fig" rid="F7">7</xref>). This delayed separation of the Kaplan-Meier curves could be due to vasopressin-induced delayed benefit of improved shock, delayed benefits of the decreased dose of norepinephrine, or effects of vasopressin on inflammation and immunity.</p><fig id="F7" position="float"><label>Figure 7</label><caption><p><bold>Survival curve for patients with more severe and less severe septic shock</bold>. Ninety-day Kaplan-Meier survival curves for patients with more severe and less severe septic shock in the Vasopressin and Septic Shock Trial comparing vasopressin-infused patients with norepinephrine-infused patients within each stratum. <bold>(a) </bold>Patients in the more severe stratum (<italic>P </italic>= 0.77 at day 28 and <italic>P </italic>= 0.92 at day 90). <bold>(b) </bold>Patients in the less severe stratum (<italic>P </italic>= 0.05 at day 28 and <italic>P </italic>= 0.03 at day 90). Solid black line, vasopressin-treated group; dotted line, norepinephrine-treated group; vertical line, day 28. <italic>P </italic>values were calculated using the log-rank statistic.</p></caption><graphic xlink:href="cc8224-7"/></fig><p>Serious adverse event rates were similar in the vasopressin and norepinephrine groups (10.3% versus 10.5%). Vasopressin infusion may increase the risk of cardiac arrest, yet in VASST there were more cardiac arrests in the norepinephrine group than in the vasopressin group (2.1% versus 0.8%, <italic>P </italic>= 0.14). Other adverse effects of vasopressin and norepinephrine are decreased cardiac output, mesenteric ischemia, hyponatremia (vasopressin), skin necrosis and digital ischemia. In VASST, there was a trend to more digital ischemia in the vasopressin group versus the norepinephrine group (2.0% versus 0.5%, <italic>P </italic>= 0.11).</p><p>VASST studied the effects of vasopressin on patients who were already receiving norepinephrine infusion. Determining whether it is the temporal influence of the combination of vasopressin plus norepinephrine or of vasopressin alone that was potentially beneficial in VASST is therefore difficult. Studies of vasopressin as the first and only agent versus vasopressin added to - and allowing tapering of - norepinephrine would resolve such controversy.</p><p>Some would argue that it may have been unrealistic to design a randomized controlled trial to detect an ARR of10% in septic shock. Indeed, if the sample size was larger, VASST could have detected a statistically significant ARR of perhaps 5% - which some would argue would be clinically significant and lead to changes in practice. For example, a sample size of 2,286 per group would have been required to have 80% power to detect a statistically significant (<italic>P </italic>&#x0003c;0.05) decrease in mortality in VASST from 39% (norepinephrine group) to 35% (vasopressin group). Similarly, a sample size of 73 per group would detect a decrease of mortality from 39% to 32%.</p><p>Strengths of VASST were the multicenter design, the large sample size powered for mortality, blinding, the use of low-dose vasopressin, blinded evaluation of serious adverse events, well-defined inclusion and exclusion criteria, and assessment of pharmacokinetics for several days of vasopressin infusion. Some limitations, however, do apply to VASST. First, the vasopressin infusion rate was predetermined for a low dose. Second, we could not measure plasma vasopressin levels to guide the dose or duration of drug infusion. Third, the MAP at baseline in VASST was about 72 to 73 mmHg, so VASST evaluated low- dose vasopressin as a catecholamine-sparing drug. Finally, the mean time from meeting the VASST inclusion criteria to study drug infusion was 12 hours - Rivers and colleagues identified benefits of early goal-directed therapy when applied in the first 6 hours [<xref ref-type="bibr" rid="B87">87</xref>], so delays greater than these 6 hours may be important. There is some evidence from VASST that early treatment with vasopressin may optimize its benefits. There was a trend to decreased mortality with vasopressin (33.2% versus norepinephrine 40.5%, <italic>P </italic>= 0.12) in patients treated within 12 hours. Early vasopressin infusion may optimize benefits similar to early goal-directed therapy [<xref ref-type="bibr" rid="B87">87</xref>].</p></sec><sec><title>Vasopressin as the initial agent in septic shock</title><p>Some would ask whether vasopressin infusion could be used as the first agent in patients who have not responded to adequate volume resuscitation, especially since vasopressin was most effective in patients who had less severe septic shock in VASST. VASST did not evaluate vasopressin as the initial agent in septic shock.</p><p>A retrospective cohort study of patients who had septic shock who received either norepinephrine (<italic>n </italic>= 49), vasopressin (<italic>n </italic>= 50), or dopamine (<italic>n </italic>= 51) as the first vasoactive agent in septic shock found no difference in mortality (65%, 52%, and 60%, respectively) [<xref ref-type="bibr" rid="B88">88</xref>]. Furthermore, there are no studies of the safety of vasopressin as the first agent in septic shock. We therefore do not believe there is yet adequate evidence to recommend vasopressin as the initial agent in septic shock.</p></sec><sec><title>Interactions of vasopressin infusion and corticosteroid treatment in septic shock</title><p>There have been remarkably few large studies of interactions of the commonly used therapies in critical care and the effects on mortality. Many of the patients in VASST were treated with corticosteroids because patients had septic shock. We therefore evaluated the interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock in VASST [<xref ref-type="bibr" rid="B89">89</xref>]. Low-dose vasopressin infusion plus corticosteroids significantly decreased 28-day mortality compared with corticosteroid plus norepinephrine treatment (44.7 to 35.9%, <italic>P </italic>= 0.03; <italic>P </italic>= 0.008 interaction statistic). In contrast, if patients were not treated with corticosteroid, then vasopressin may have increased mortality compared with nor-epinephrine (33.7 versus 21.3% respectively, <italic>P </italic>= 0.06). In patients who received vasopressin infusion, corticosteroids increased plasma vasopressin levels significantly to 33% at 6 hours (<italic>P </italic>= 0.001) and to 67% at 24 hours (<italic>P </italic>= 0.032) versus patients who did not receive corticosteroids.</p><p>To the knowledge of the VASST investigators, this substudy of VASST is the first clinical study of interactions of vasopressin and corticosteroids on mortality and organ dysfunction in human septic shock. Many patients probably receive the combination of vasopressin and corticosteroids in clinical practice. Despite this, there are few studies of the interaction of vasopressin and corticosteroids in septic shock. The effects of corticosteroids on vasopressin levels and efficacy are controversial. Studies find that corticosteroids increase vasopressin mRNA and restore responsiveness to vasopressin, have no effect on vasopressin levels, and even suppress vasopressin gene expression [<xref ref-type="bibr" rid="B90">90</xref>-<xref ref-type="bibr" rid="B93">93</xref>].</p><p>The effects of vasopressin on the corticosteroid axis are clearer [<xref ref-type="bibr" rid="B90">90</xref>,<xref ref-type="bibr" rid="B94">94</xref>,<xref ref-type="bibr" rid="B95">95</xref>]. When vasopressin binds to AVR1b (V3 receptor), vasopressin increases corticotroph responsiveness to corticotropin-releasing factor, thus increasing ACTH even in conditions of stress when corticosteroid levels are increased [<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B75">75</xref>,<xref ref-type="bibr" rid="B90">90</xref>,<xref ref-type="bibr" rid="B94">94</xref>,<xref ref-type="bibr" rid="B95">95</xref>]. The vasopressin-induced increase of ACTH (unlike effects of corticotropin-releasing factor on ACTH) is resistant to corticosteroid-negative feedback because binding to AVR1b is coupled to phospholipase C and is not regulated by corticosteroid levels. Vasopressin infusion did not change serum ACTH or cortisol levels in a cohort of septic shock [<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B75">75</xref>].</p><p>It is not known how vasopressin plus corticosteroids (versus norepinephrine plus corticosteroids) could have altered mortality rates. Potential mechanisms could be that corticosteroids increased vasopressin levels or enhanced responsiveness to vasopressin [<xref ref-type="bibr" rid="B91">91</xref>], or the combination of vasopressin and corticosteroids altered inflammation and immunity beneficially. Annane suggested that interactions with nitric oxide could explain this interaction [<xref ref-type="bibr" rid="B96">96</xref>]. Furthermore, vasopressinases such as LNPEP catalyze the metabolism of vasopressin in the circulation. Interestingly, LNPEP and other vasopressinases are corticosteroid responsive [<xref ref-type="bibr" rid="B96">96</xref>].</p><p>The effects of corticosteroids on vasopressin receptors have not been extensively studied. Dexamethasone attenuates the downregulation of AVPR1a receptors in sepsis by inhibition of NF&#x003ba;B.</p></sec><sec><title>Use of higher doses of vasopressin</title><p>Several investigators have explored the use of higher doses of vasopressin in septic shock [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B73">73</xref>-<xref ref-type="bibr" rid="B75">75</xref>], and indeed have argued that this is one reason why vasopressin might not have decreased mortality in VASST [<xref ref-type="bibr" rid="B97">97</xref>]. Cohort studies, case-control studies, and small randomized controlled trials have used doses of vasopressin of about 0.06 units/minute (compared with 0.03 units/minute in VASST), and found that vasopressin significantly decreased use of norepinephrine and increased blood pressure [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B75">75</xref>]. Some of these studies, however, also detected potentially adverse side effects of vasopressin such as decreased intestinal mucosal perfusion [<xref ref-type="bibr" rid="B98">98</xref>,<xref ref-type="bibr" rid="B99">99</xref>], increased bilirubin [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>], increased serum transaminases [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B75">75</xref>], and decreased platelet counts [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B73">73</xref>]. Note that some of these studies used much higher doses than recommended in human septic shock [<xref ref-type="bibr" rid="B98">98</xref>-<xref ref-type="bibr" rid="B100">100</xref>]. We have agreed with the suggestion [<xref ref-type="bibr" rid="B97">97</xref>] that a large randomized trial of these higher doses of vasopressin (0.06 units/minute) to address safety and efficacy questions in septic shock is meritorious [<xref ref-type="bibr" rid="B97">97</xref>].</p></sec><sec><title>Other AVPR1A agonists: terlipressin and others</title><p>There are a number of alternatives to vasopressin in septic shock (including ornipressin, terlipressin, specific AVPR1a agonists, and others), of which terlipressin has been most studied [<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B101">101</xref>-<xref ref-type="bibr" rid="B112">112</xref>]. Terlipressin is a 12-amino-acid synthetic analog of lysine vasopressin, a precursor of vasopressin, and has a longer elimination half-life than vasopressin (50 minutes for terlipressin compared with 6 minutes for vasopressin) [<xref ref-type="bibr" rid="B113">113</xref>-<xref ref-type="bibr" rid="B116">116</xref>]. Terlipressin also has greater selectivity for the AVPR1a receptor than does vasopressin [<xref ref-type="bibr" rid="B110">110</xref>,<xref ref-type="bibr" rid="B113">113</xref>]. Terlipressin is metabolized by exopeptidases to yield small sustained levels of lysine vasopressin in the circulation, accounting for its longer biological half-life compared with native vasopressin. Similar to vasopressin, terlipressin increases blood pressure, decreases dose requirements for norepinephrine in septic shock and increases renal function (urine output and creatinine clearance) [<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B101">101</xref>,<xref ref-type="bibr" rid="B104">104</xref>-<xref ref-type="bibr" rid="B107">107</xref>]. Terlipressin may be effective for transporting patients with septic shock who are on norepinephrine because of the relatively long half-life of terlipressin [<xref ref-type="bibr" rid="B117">117</xref>]. Terlipressin improves renal function and outcomes of hepatorenal syndrome [<xref ref-type="bibr" rid="B118">118</xref>-<xref ref-type="bibr" rid="B120">120</xref>] and so, like vasopressin [<xref ref-type="bibr" rid="B121">121</xref>], could also improve renal function in septic shock. Terlipressin may also be given as a continuous infusion [<xref ref-type="bibr" rid="B122">122</xref>-<xref ref-type="bibr" rid="B125">125</xref>], which then increases blood pressure, decreases dose requirements of norepinephrine, and may have less rebound hypotension when discontinued compared with vasopressin [<xref ref-type="bibr" rid="B122">122</xref>].</p><p>Like vasopressin [<xref ref-type="bibr" rid="B73">73</xref>], terlipressin may decrease cardiac output in septic shock [<xref ref-type="bibr" rid="B101">101</xref>], especially if there is myocardial depression or pre-existing myocardial dysfunction (such as pre-existing congestive heart failure, ongoing myocardial ischemia) [<xref ref-type="bibr" rid="B126">126</xref>]. The decrease of cardiac output due to terlipressin is prevented in animals [<xref ref-type="bibr" rid="B126">126</xref>] and humans by co-administration of dobutamine [<xref ref-type="bibr" rid="B111">111</xref>], which increases the left ventricular stroke work index [<xref ref-type="bibr" rid="B111">111</xref>]. Furthermore, terlipressin may increase coronary vasoconstriction [<xref ref-type="bibr" rid="B127">127</xref>] and induce myocardial ischemia because both vasopressin and terlipressin may potentiate adrenergic vasoconstriction in coronary arteries [<xref ref-type="bibr" rid="B128">128</xref>] (as well as mesenteric arteries [<xref ref-type="bibr" rid="B129">129</xref>]). Terlipressin may also have direct coronary vasoconstrictive properties because of binding to AVPR1a [<xref ref-type="bibr" rid="B127">127</xref>]. Terlipressin has been associated with ventricular arrhythmias [<xref ref-type="bibr" rid="B130">130</xref>], with decreased platelet counts [<xref ref-type="bibr" rid="B101">101</xref>,<xref ref-type="bibr" rid="B122">122</xref>] and - similar to vasopressin [<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B79">79</xref>,<xref ref-type="bibr" rid="B107">107</xref>] - with mesenteric ischemia, in part because both agents may potentiate adrenergic vasoconstriction in the mesenteric circulation [<xref ref-type="bibr" rid="B129">129</xref>].</p></sec><sec><title>Conundrums and one view to consensus</title><p>There are conundrums in the vasopressin literature. Large clinical trials such as VASST suggest that vasopressin may be more effective in patients who have less severe septic shock and in combination with corticosteroids. Yet experimental studies suggest that AVPR1a sensitivity and the prevalence of adrenal dysfunction increase with severity of shock. The conflicting evidence about AVPR1a sensitivity (some studies suggest increased AVPR1a sensitivity while others found less sensitivity in models of sepsis) suggests this is an ongoing controversy. Regarding the interaction of vasopressin and corticosteroids, perhaps the beneficial interaction is not related to the presence of adrenal dysfunction but rather is related to corticosteroid-induced increase of vasopressin levels [<xref ref-type="bibr" rid="B52">52</xref>,<xref ref-type="bibr" rid="B89">89</xref>]. Vasopressin levels were higher in patients who had preserved adrenal function - and higher corticosteroid levels - compared with patients who had impaired adrenal function (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>Another puzzle is the observation that the efficacy of corticosteroids is only moderate in moderate septic shock (CORTICUS) [<xref ref-type="bibr" rid="B86">86</xref>] and is greater in more severe septic shock. We have recently shown that corticosteroids appear to increase plasma vasopressin levels in both less severe and more severe septic shock, but the effect was statistically significant only in less severe septic shock. The beneficial interaction of vasopressin infusion and corticosteroid treatment may therefore span the spectrum of severity of shock.</p><p>Another question is the relationship of vasopressin to dopamine, to dobutamine plus norepinephrine, and to epinephrine - considering that VASST focused on patients of whom the majority were already on norepinephrine infusion. In VASST, some patients were on dopamine or epinephrine instead of norepinephrine; however, the numbers of these patients were too small to assess accurately the effects of vasopressin on patients who were receiving these vasoactive agents. It is likely that the findings of studies of vasopressin effects on norepinephrine dose also apply to dopamine when dopamine is used as a vasopressor (that is, doses &#x0003e;5 &#x003bc;g/kg/minute). It is quite likely that vasopressin can be used effectively with dobutamine because several animal and human studies have shown that the combination of vasopressin and dobutamine is beneficial in limiting any decrease of cardiac output, oxygen delivery, and mixed venous oxygen saturation caused by vasopressin. It is also likely that vasopressin may also be used in patients who are already on epinephrine infusion. The combination of dopexamine and vasopressin attenuated decreases of the cardiac index and oxygen delivery - compared with vasopressin alone - but dopexamine also decreased blood pressure compared with vasopressin; this suggests that dopexamine may not be a good agent to attenuate cardiovascular adverse effects of vasopressin.</p><p>Clearly there is a common, profound deficiency of vasopressin in septic shock. However, it is not known when and how quickly this vasopressin deficiency recovers. Siami and colleagues addressed this important question by measuring plasma vasopressin levels of normonatremic patients who had septic shock for more than 72 hours who were given a stimulus: osmotic stimulation using 500 ml hypertonic saline [<xref ref-type="bibr" rid="B131">131</xref>]. Interestingly, 52% (17 of 33 patients) of patients were nonresponders to this stimulation. In responders, plasma vasopressin increased from 4.8 to 14.4 pg/ml, a rate of increase of 6.2 pg/ml/hour. In contrast, nonresponders' plasma vasopressin did not increase significantly (from 2.8 to 4 pg/ml, a rate of increase of 0.7 pg/ml/hour). Nonresponders were more frequently bacteremic and had hepatic dys-function compared with responders. Hypertonic saline lead to comparable changes in central venous pressure, MAP and systolic arterial pressure in responders and nonresponders; thus, it is unlikely that the differences in response of plasma vasopressin levels were due to differences in baroreceptor reflex stimulation. Osmoregulation by vasopressin is therefore impaired in about one-half of this small sample of patients who had sustained septic shock. It is likely that vasopressin regulation of blood pressure is similarly impaired for at least this duration.</p><p>What is the status of the vasopressin axis shortly after patients are weaned off vasopressin infusion? Bauer and colleagues found that patients dropped their blood pressure more often when vasopressin infusion was stopped before stopping infusion of norepinephrine [<xref ref-type="bibr" rid="B132">132</xref>]. Their study suggests there can be ongoing inadequate vasopressin axis reserve. This hypothesis is not directly known, but the vasopressin axis is probably only partially recovered for some time after discontinuation of vasopressin infusion and a secondary insult (for example, new nosocomial infection) might lead to septic shock more readily because of continued impaired vasopressin axis responses.</p></sec><sec><title>Newer alternative strategies to support ventricular function in patients whose ventricular function declines on vasopressin</title><p>Vasopressin infusion has been reported to decrease cardiac output in some patients who have septic shock. Dobutamine infusion is often added to increase cardiac output [<xref ref-type="bibr" rid="B133">133</xref>]. Levosimendan is a novel inotropic agent that acts by sensitizing calcium channels leading to vasodilatation, and often (but not always) leading to increases in cardiac output. Rehberg and colleagues showed that levosimendan plus vasopressin improved aspects of hemodynamic parameters (such as the left ventricular stroke work index) and net fluid balance in sheep that had fecal peritonitis compared with vasopressin therapy alone [<xref ref-type="bibr" rid="B134">134</xref>]. The combination of vasopressin plus levosimendan also increased global perfusion (as assessed by mixed venous oxygen saturation) and decreased pulmonary artery pressure. This novel combination also appeared to improve the net fluid balance and prevented decreases in colloid osmotic pressure compared with vasopressin alone. Levosimendan is not yet available for clinical use in North America, but its study is intriguing and bears further clinical evaluation.</p><p>If patients suffer a decrease of cardiac output and tissue perfusion in response to vasopressin, therefore, one should re-evaluate the volume status - volume resuscitate if deficient, and if volume replete the current evidence supports adding dobutamine infusion to augment cardiac output.</p></sec><sec><title>Genomics and vasopressin</title><p>Recent studies suggest that there could be notable genomic variation in vasopressinases (also known as LNPEP), the enzyme that metabolizes vasopressin (as well as oxytocin and GLUT4). Furthermore, Nakada and colleagues found that patients who had the genotype TT of the single nucleotide polymorphism rs4869317 of the LNPEP gene had increased mortality (compared with patients who had the AT/AA genotypes) in a discovery cohort of patients who had septic shock, and that this finding was replicated in an independent cohort of patients who had septic shock [<xref ref-type="bibr" rid="B135">135</xref>]. This marker (rs4860317 TT) was also associated with increased cardiovascular dysfunction. Furthermore, these authors discovered that patients who were on a vasopressin infusion who had the rs4869317 TT genotype had lower plasma vasopressin concentrations because of increased vasopressin clearance [<xref ref-type="bibr" rid="B135">135</xref>]. To summarize, the TT genotype of rs4869317 was associated with increased mortality and increased vasopressin clearance in patients who had septic shock.</p><p>Patients who have the TT genotype of rs4869317 would also be expected to have altered AVPR1a and AVPR2 responses to vasopressin because of altered vasopressin levels available to these different vasopressin receptors. Indeed, the plasma sodium concentration was higher in the first 48 hours of cardiovascular surgery in patients who had the rs4869317 TT genotype compared with patients who had the AT/AA genotypes. This finding aligns with the diminished vasopressin levels and increased mortality rates of patients with the TT genotype of rs4869317 who had septic shock. The genomic variation of the LNPEP gene of patients could therefore alter the response to vasopressin (and other vasopressin analogues) in septic shock, postcardiovascular surgery and other conditions such as hepatorenal syndrome.</p><p>The role for the use of genetic testing to provide more patient-centered care is exciting, requires more investigation and could be of benefit in the selection of patients for treatment with vasopressin or vasopressin analogs.</p></sec><sec><title>New conditions in which there is a vasopressin deficiency</title><p>Patients with end-stage liver disease characteristically have a vasodilated circulation that can mimic sepsis and septic shock. Therefore it is reasonable to hypothesize that there could be a vasopressin deficiency in such patients. Wagener and colleagues evaluated a cohort of such patients by measuring plasma vasopressin levels and responses to infusion of vasopressin [<xref ref-type="bibr" rid="B136">136</xref>]. Plasma vasopressin levels were inappropriately low in patients who had end- stage hepatic disease undergoing liver transplantation compared with control surgical patients. Vasopressin increased systemic vascular resistance and arterial pressure. Patients who have end-stage hepatic disease thus appear to have vasopressin deficiency and may benefit from vasopressin infusion (once fluid resuscitation is adequate).</p><p>These observations of potential benefits of vasopressin in end-stage liver disease are congruent with the studies showing benefits of terlipressin in patients who have severe liver disease and renal dysfunction - hepatorenal syndrome.</p></sec><sec><title>More selective V1a agonism in septic shock: another approach</title><p>As discussed, there could be advantages to more selective V1a agonism treatment in septic shock such as purer vasoconstriction, limited antidiuretic effects, lack of stimulation of thrombosis (because of lower increase of von Willebrand multimers) and perhaps better protection from increased permeability. Rehberg and colleagues designed a clever study in which they gave a V2 receptor antagonist (propionyl-1-d-(Tyr(Et)2-Val4-Abu6-Arg8,9)-vasopressin) with or without a V1a agonist (arginine vasopressin) or placebo to chronically instrumented sheep who had early septic shock [<xref ref-type="bibr" rid="B137">137</xref>]. This V2 receptor antagonist with arginine vasopressin maintained hemodynamics (cardiac index and MAP) and increased the left ventricular stroke work index. Most notably, the combination of the V2 receptor antagonist with arginine vasopressin (compared with arginine vasopressin alone) improved markers of tissue perfusion (for example, pH and arterial lactate), while also attenuating liver and renal dysfunction. Markers of lung injury (hemeoxygenase and 3-nitrotyrosine concentrations) were also more favorably protected in the animals that received this combination of V2 receptor antagonist with arginine vasopressin compared with arginine vasopressin alone. Also intriguing is the observation that the administration of arginine vasopressin alone increased plasma vasopressin levels, whereas the combination of this V2 receptor antagonist with arginine vasopressin increased plasma vasopressin levels to a lesser degree.</p><p>This innovative animal model study provides further evidence to support further clinical investigation into the role of selective V1a agonism in human septic shock.</p></sec><sec><title>Clinical perspectives</title><p>What should the clinician do in considering use of vasopressin in patients who have septic shock? My current recommendations are to consider use of vasopressin in patients who have less severe septic shock because of the encouraging effects of vasopressin in these patients in VASST [<xref ref-type="bibr" rid="B52">52</xref>].</p><p>Should vasopressin levels be measured in patients who have septic shock? One obstacle is that vasopressin can only be measured by radioimmunoassay, which is relatively cumbersome and has too great a turnaround time for patients who have septic shock. I would therefore not recommend measurement of vasopressin levels (or copeptin levels, as already discussed on page 6 above) at this time for clinical purposes in patients who have septic shock. I would recommend that vasopressin be given as a continuous infusion not exceeding 0.03 units/minute, because that was the dose used in VASST.</p><p>Should vasopressin be used as first-line therapy in hypotensive septic patients? I believe this is a useful question for clinical research but not yet for clinical practice.</p><p>Should vasopressin and corticosteroids be given together? The potentially beneficial interaction of vasopressin infusion and corticosteroid treatment on mortality was discovered in a <italic>post hoc </italic>substudy of VASST and could be a false positive, and so is hypothesis-generating at this time. The Surviving Sepsis Guidelines [<xref ref-type="bibr" rid="B85">85</xref>] state that norepinephrine and vasopressin are similar and that vasopressin should be considered in patients who have septic shock.</p></sec><sec><title>Future research</title><p>Some themes for future research could include assessment of vasopressin as the first-line agent in septic shock, evaluation of the renal effects of vasopressin, further assessment of adverse effects of vasopressin versus norepinephrine, and use of the more specific AVPR1a agonist. Preliminary reports suggest that an AVPR1a agonist causes less third-spacing of fluid (vascular leak syndrome), could reduce release of the procoagulant protein von Willebrand factor (released by stimulation of AVPR2), and decreases mortality compared with vasopressin in two different models of septic shock.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Vasopressin stimulates a family of receptors (AVPR1a, AVPR1b, and AVPR2). AVPR1a is responsible for the vasoconstriction associated with vasopressin. Sepsis may downregulate all three vasopressin receptors. Vasopressin levels increase early in septic shock because hypotension is the most potent stimulus for release of stored vasopressin. Vasopressin levels then decline rapidly - due to depletion of stored vasopressin.</p><p>Responses to vasopressin and norepinephrine are modified in sepsis and, furthermore, the effects of vasopressin differ in different vascular beds in sepsis. Vasopressin infusion increases blood pressure, decreases norepinephrine dose requirements, and improves renal function. Previous clinical studies of vasopressin in septic shock, however, were small or not controlled. Adverse effects of vasopressin include mesenteric ischemia, myocardial ischemia, digital ischemia, skin necrosis, and hyponatremia.</p><p>VASST, a randomized controlled trial of vasopressin versus norepinephrine in septic shock, was performed to address uncertainties regarding efficacy and safety of vasopressin in septic shock. There was no significant difference between vasopressin-treated and norepinephrine-treated groups in 28-day mortality (35.4% versus 39.3%, <italic>P </italic>= 0.26; ARR = -2.9 to 10.7%) or in organ dysfunction rates. Vasopressin may have decreased mortality in patients who had less severe septic shock in VASST. Serious adverse event rates were similar in the vasopressin and norepinephrine groups.</p><p>Vasopressin therefore appears equally as safe as norepinephrine in septic shock, and may improve mortality in less severe septic shock. There have been remarkably few large studies of interactions of the commonly used therapies in critical care and the effects on mortality. Low-dose vasopressin infusion plus corticosteroids significantly decreased 28-day mortality compared with corticosteroids plus norepinephrine (44.7 to 35.9%, <italic>P </italic>= 0.03; <italic>P </italic>= 0.008 interaction statistic). This interaction is potentially important and requires further study.</p></sec><sec><title>Summary</title><p>Low-dose vasopressin may be effective in patients already receiving norepinephrine who have less severe septic shock - such as patients with modest norepinephrine infusion (5 to 15 &#x003bc;g/minute) or low serum lactate levels. Additional studies such as large randomized controlled trials are necessary to address questions regarding higher doses of vasopressin, use of vasopressin as the first agent in septic shock, use of terlipressin and other more specific AVPR1a agonists, and the interaction of vasopressin and corticosteroids in septic shock.</p></sec><sec><title>Abbreviations</title><p>ACTH: adrenocorticotropic hormone; ARR: absolute risk reduction; IFN: interferon; IL: interleukin; MAP: mean arterial pressure; TNF: tumor necrosis factor; VASST: Vasopressin and Septic Shock Trial.</p></sec><sec><title>Competing interests</title><p>JAR reports holding stock in Sirius Genomics Incorporated, which has submitted patents owned by the University of British Columbia and licensed to Sirius Genomics, that are related to the genetics of vasopressin, NIK and protein C. The University of British Columbia has also submitted a patent related to the use of vasopressin in septic shock. JAR is an inventor on these patents. JAR reports receiving consulting fees from Ferring, which manufactures vasopressin, from Astra Zeneca which manufactures anti-TNF, from Sirius Genomics Inc., and from Biocritica which sells activated protein C in the USA. JAR reports receiving grant support from Sirius Genomics, Novartis, Ferring, and Eli Lilly. JAR has received speaking honoraria from Pfizer and Eli Lilly.</p></sec></body><back><sec><title>Acknowledgements</title><p>Support for VASST from the Canadian Institutes of Health Research (grant number MCT 44152). Registration: ISRCTN94845869.</p><p>In addition to the author, the following persons and institutions participated in the VASST trial: Writing Committee - J.A. Russell (chair), K.R. Walley,</p><p>A.C. Gordon, C. Holmes Boulton, J.T. Granton, P.C. Hebert, D.J. Cooper, S. Mehta, J. Singer, D.J. Cook, J.J. Presneill, M.M. Storms; Executive Committee - J.A. Russell (chair), K.R. Walley, C.L. Holmes Boulton, J.T. Granton, P.C. Hebert, D.J. Cooper, S. Mehta, J. Singer, A.C. Gordon, M.M. Storms (project coordinator), S. Jones (administrative assistant); Management Committee - J.A. Russell (chair), M.M. Storms (project coordinator), K.R. Walley, C.L. Holmes Boulton, J. Singer, A.C. Gordon, S. Jones (administrative assistant); DSMB - G.R. Bernard (chair), A.S. Slutsky, G.A Wells; CIHR - A. Gasparini; Data Management - Singer, B. Savage, D. Ayers, R. Woods, K. Wu, M. Maralit; Monitoring <bold>- </bold>L. Smith, K. Foley, A. Suri, M. Steinberg, B. Howe, P. Galt, A. Higgins, M.M. Storms; Laboratory - M.E. LeBlanc, A.M. Sutherland, A. Sham, A. McLeod.</p><p>Clinical centers and VASST investigators</p><p>Canada</p><p><italic>British Columbia</italic>: St Paul's Hospital - J.A. Russell, K.R. Walley, D.R. Dorscheid, M. Hameed, L. Lazosky, S. Helderweirt, K. Foley, C. Honeyman, T. Terins; Vancouver General Hospital - D. Chittock, J. Ronco, L. Smith, S. Logie; Royal Jubilee Hospital - G. Wood, F. Auld; Kelowna General Hospital - C. Holmes Boulton, V. Stedham, M. Mantle, L. Fox, G.D. McCauley, J.D. Rolf, C. Erbacher; Richmond General Hospital - G. Martinka, S. Goulding, S. Silverwood, L. Leung; Royal Columbian Hospital - S. Keenan, J. Murray, M. Van Osch.</p><p><italic>Manitoba</italic>: St Boniface Hospital - B. Light, M. Dominique; Winnipeg Health Science Centre - P. Gray, R. Stimpson, S. Rosser, D. Bell, W. Janz.</p><p><italic>Ontario</italic>: Ottawa Hospital, General Campus - P.C. Hebert, T. McArdle, I. Watpool; UHN - Toronto General &#x00026; Toronto Western Hospitals - J.T. Granton, M. Steinberg, A. Matte-Martyn; St Joseph's Hospital - D.J Cook, E. McDonald, F. Clarke, A. Tkaczyk, N. Zytaruk; Mount Sinai Hospital - S. Mehta, T. Stewart, A. Suri, C. Martinez-Motta, R. MacDonald, V. Sivanantham; Ottawa Hospital, Civic Campus - R. Hodder, J. Foxall, M. Lewis; St Michael's Hospital - M. Ward, C. Dos Santos, J. Friedrich, D. Scales, O. Smith, I. DeCampos, A. Richards, H. Michalopoulos, U. Bakshi; Sunnybrook and Women's College Health Science Centre - W. Sibbald, T. Smith, K. Code, B. Bojilov, C. Dale, M. Keogh; Hamilton Health Sciences Centre - M. Meade, L. Hand; London Health Sciences Centre - C. Martin, J. Kehoe, V. Binns; Sudbury Regional Hospital - M. Mehta, M. McGuire; Charles LeMoyne Hospital - G. Poirier, L. Provost; Windsor - Hotel Dieu Hospital - J. Muscedere, C. Diemer.</p><p>Australia</p><p><italic>Victoria</italic>: Alfred Hospital - D.J. Cooper, V. Pellegrino, A. Hilton, S. Morrison, C. Weatherburn, K. Moulden, C. Harry; Royal Melbourne - J.J. Presneill, M. S Robertson, J.F. Cade, B.D. Howe, D.K. Barge, C.A. Boyce, F. Healy; Monash Medical Center - C. Wright, D. Weyandt, J. Barrett, C. Walker, P. Galt, S. Burton. <italic>Western Australia</italic>: Royal Perth Hospital - G. Dobb, S. Perryman, J. Chamberlain, L. Thomas.</p><p><italic>South Australia</italic>: Flinders Medical Centre - A. Bersten, L. Daly, T. Hunt, D. Wood.</p><p>USA</p><p>Mayo Hospital - B. Patel, J. Larson, M. Rady, G. LeBrun, E. Boyd, R. Rush.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Auzan</surname><given-names>C</given-names></name><name><surname>Madhun</surname><given-names>Z</given-names></name><name><surname>Wilkins</surname><given-names>P</given-names></name><name><surname>Berti-Mattera</surname><given-names>L</given-names></name><name><surname>Clauser</surname><given-names>E</given-names></name><article-title>Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>3304</fpage><lpage>3310</lpage><pub-id pub-id-type="pmid">8106369</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Graves</surname><given-names>MK</given-names></name><name><surname>Wagner</surname><given-names>MS</given-names></name><name><surname>Chatelain</surname><given-names>N</given-names></name><name><surname>Soubrier</surname><given-names>F</given-names></name><name><surname>Corvol</surname><given-names>P</given-names></name><name><surname>Willard</surname><given-names>HF</given-names></name><name><surname>Jeunemaitre</surname><given-names>X</given-names></name><article-title>Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension</article-title><source>J Mol Cell Cardiol</source><year>2000</year><volume>324</volume><fpage>557</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">10756113</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Berrada</surname><given-names>K</given-names></name><name><surname>Plesnicher</surname><given-names>CL</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Thibonnier</surname><given-names>M</given-names></name><article-title>Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>27229</fpage><lpage>27237</lpage><pub-id pub-id-type="pmid">10858434</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Ayajiki</surname><given-names>K</given-names></name><name><surname>Fujioka</surname><given-names>H</given-names></name><name><surname>Toda</surname><given-names>N</given-names></name><article-title>Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries</article-title><source>J Hypertens</source><year>1999</year><volume>17</volume><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1097/00004872-199917050-00011</pub-id><pub-id pub-id-type="pmid">10403611</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Pearson</surname><given-names>PJ</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><article-title>Arginine vasopressin induces endotheliumdependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide</article-title><source>Chest</source><year>1993</year><volume>103</volume><fpage>1241</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1378/chest.103.4.1241</pub-id><pub-id pub-id-type="pmid">8131474</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Russ</surname><given-names>RD</given-names></name><name><surname>Walker</surname><given-names>BR</given-names></name><article-title>Role of nitric oxide in vasopressinergic pulmonary vasodilatation</article-title><source>Am J Physiol</source><year>1992</year><volume>262</volume><issue>3 Pt 2</issue><fpage>H743</fpage><lpage>H747</lpage><pub-id pub-id-type="pmid">1558183</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Sai</surname><given-names>Y</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Amakata</surname><given-names>Y</given-names></name><name><surname>Toda</surname><given-names>N</given-names></name><article-title>Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin</article-title><source>Eur J Pharmacol</source><year>1995</year><volume>282</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(95)00343-J</pub-id><pub-id pub-id-type="pmid">7498282</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Young</surname><given-names>LJ</given-names></name><name><surname>Gonen</surname><given-names>D</given-names></name><name><surname>Veenstra-VanderWeele</surname><given-names>J</given-names></name><name><surname>Courchesne</surname><given-names>R</given-names></name><name><surname>Courchesne</surname><given-names>E</given-names></name><name><surname>Lord</surname><given-names>C</given-names></name><name><surname>Leventhal</surname><given-names>BL</given-names></name><name><surname>Cook</surname><given-names>EH</given-names><suffix>Jr</suffix></name><name><surname>Insel</surname><given-names>TR</given-names></name><article-title>Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism</article-title><source>Mol Psychiatry</source><year>2002</year><volume>7</volume><fpage>503</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001125</pub-id><pub-id pub-id-type="pmid">12082568</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Knafo</surname><given-names>A</given-names></name><name><surname>Israel</surname><given-names>S</given-names></name><name><surname>Darvasi</surname><given-names>A</given-names></name><name><surname>Bachner-Melman</surname><given-names>R</given-names></name><name><surname>Uzefovsky</surname><given-names>F</given-names></name><name><surname>Cohen</surname><given-names>L</given-names></name><name><surname>Feldman</surname><given-names>E</given-names></name><name><surname>Lerer</surname><given-names>E</given-names></name><name><surname>Laiba</surname><given-names>E</given-names></name><name><surname>Raz</surname><given-names>Y</given-names></name><name><surname>Nemanov</surname><given-names>L</given-names></name><name><surname>Gritsenko</surname><given-names>I</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><article-title>Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA</article-title><source>Genes Brain Behav</source><year>2008</year><volume>7</volume><fpage>266</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/j.1601-183X.2007.00341.x</pub-id><pub-id pub-id-type="pmid">17696996</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Bucher</surname><given-names>M</given-names></name><name><surname>Hobbhahn</surname><given-names>J</given-names></name><name><surname>Taeger</surname><given-names>K</given-names></name><name><surname>Kurtz</surname><given-names>A</given-names></name><article-title>Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2002</year><volume>282</volume><fpage>R979</fpage><lpage>R984</lpage><pub-id pub-id-type="pmid">11893600</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Spitzer</surname><given-names>JA</given-names></name><article-title>Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion</article-title><source>Am J Physiol</source><year>1987</year><volume>252</volume><issue>5 Pt 1</issue><fpage>E699</fpage><lpage>E702</lpage><pub-id pub-id-type="pmid">3034072</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>LK</given-names></name><name><surname>Orie</surname><given-names>NN</given-names></name><name><surname>Taylor</surname><given-names>V</given-names></name><name><surname>Stidwill</surname><given-names>RP</given-names></name><name><surname>Clapp</surname><given-names>LH</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><article-title>Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>2337</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000281861.72907.17</pub-id><pub-id pub-id-type="pmid">17944022</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Antoni</surname><given-names>FA</given-names></name><name><surname>Holmes</surname><given-names>MC</given-names></name><name><surname>Makara</surname><given-names>GB</given-names></name><name><surname>Karteszi</surname><given-names>M</given-names></name><name><surname>Laszlo</surname><given-names>FA</given-names></name><article-title>Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor</article-title><source>Peptides</source><year>1984</year><volume>5</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/0196-9781(84)90080-9</pub-id><pub-id pub-id-type="pmid">6089144</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Hernando</surname><given-names>F</given-names></name><name><surname>Schoots</surname><given-names>O</given-names></name><name><surname>Lolait</surname><given-names>SJ</given-names></name><name><surname>Burbach</surname><given-names>JP</given-names></name><article-title>Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin</article-title><source>Endocrinology</source><year>2001</year><volume>142</volume><fpage>1659</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1210/en.142.4.1659</pub-id><pub-id pub-id-type="pmid">11250948</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Lolait</surname><given-names>SJ</given-names></name><name><surname>Stewart</surname><given-names>LQ</given-names></name><name><surname>Jessop</surname><given-names>DS</given-names></name><name><surname>Young</surname><given-names>WS</given-names></name><name><surname>O'Carroll</surname><given-names>AM</given-names></name><article-title>The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors</article-title><source>Endocrinology</source><year>2007</year><volume>148</volume><fpage>849</fpage><lpage>856</lpage><pub-id pub-id-type="pmid">17122081</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>de Keyzer</surname><given-names>Y</given-names></name><name><surname>Lenne</surname><given-names>F</given-names></name><name><surname>Auzan</surname><given-names>C</given-names></name><name><surname>Jegou</surname><given-names>S</given-names></name><name><surname>Rene</surname><given-names>P</given-names></name><name><surname>Vaudry</surname><given-names>H</given-names></name><name><surname>Kuhn</surname><given-names>JM</given-names></name><name><surname>Luton</surname><given-names>JP</given-names></name><name><surname>Clauser</surname><given-names>E</given-names></name><name><surname>Bertagna</surname><given-names>X</given-names></name><article-title>The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome</article-title><source>J Clin Invest</source><year>1996</year><volume>97</volume><fpage>1311</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1172/JCI118547</pub-id><pub-id pub-id-type="pmid">8636444</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>O'Connor</surname><given-names>PM</given-names></name><name><surname>Cowley</surname><given-names>AW</given-names><suffix>Jr</suffix></name><article-title>Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway</article-title><source>Am J Physiol Renal Physiol</source><year>2007</year><volume>293</volume><fpage>F526</fpage><lpage>F532</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00052.2007</pub-id><pub-id pub-id-type="pmid">17507604</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>F</given-names></name><name><surname>Zou</surname><given-names>AP</given-names></name><name><surname>Cowley</surname><given-names>AW</given-names><suffix>Jr</suffix></name><article-title>Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla</article-title><source>Hypertension</source><year>1998</year><volume>32</volume><fpage>896</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">9822450</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Borgel</surname><given-names>D</given-names></name><name><surname>Lerolle</surname><given-names>N</given-names></name><name><surname>Feys</surname><given-names>HB</given-names></name><name><surname>Trinquart</surname><given-names>L</given-names></name><name><surname>Vanhoorelbeke</surname><given-names>K</given-names></name><name><surname>Deckmyn</surname><given-names>H</given-names></name><name><surname>Legendre</surname><given-names>P</given-names></name><name><surname>Diehl</surname><given-names>JL</given-names></name><name><surname>Baruch</surname><given-names>D</given-names></name><article-title>Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>2375</fpage><lpage>2382</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000284508.05247.B3</pub-id><pub-id pub-id-type="pmid">17944029</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Mimuro</surname><given-names>J</given-names></name><name><surname>Madoiwa</surname><given-names>S</given-names></name><name><surname>Soejima</surname><given-names>K</given-names></name><name><surname>Kashiwakura</surname><given-names>Y</given-names></name><name><surname>Ishiwata</surname><given-names>A</given-names></name><name><surname>Takano</surname><given-names>K</given-names></name><name><surname>Ohmori</surname><given-names>T</given-names></name><name><surname>Sakata</surname><given-names>Y</given-names></name><article-title>Severe secondary deficiency of von Willebrand factorcleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>528</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-03-1087</pub-id><pub-id pub-id-type="pmid">16189276</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Hocherl</surname><given-names>K</given-names></name><name><surname>Kurt</surname><given-names>B</given-names></name><name><surname>Bucher</surname><given-names>M</given-names></name><article-title>Role of nuclear factor-&#x003ba;Bdependent induction of cytokines in the regulation of vasopressin V1A-receptors during cecal ligation and puncture-induced circulatory failure</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>2363</fpage><lpage>2372</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318180b51d</pub-id><pub-id pub-id-type="pmid">18596633</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Grinevich</surname><given-names>V</given-names></name><name><surname>Knepper</surname><given-names>MA</given-names></name><name><surname>Verbalis</surname><given-names>J</given-names></name><name><surname>Reyes</surname><given-names>I</given-names></name><name><surname>Aguilera</surname><given-names>G</given-names></name><article-title>Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00378.x</pub-id><pub-id pub-id-type="pmid">14675036</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Qahwash</surname><given-names>IM</given-names></name><name><surname>Cassar</surname><given-names>CA</given-names></name><name><surname>Radcliff</surname><given-names>RP</given-names></name><name><surname>Smith</surname><given-names>GW</given-names></name><article-title>Bacterial lipopolysaccharideinduced coordinate downregulation of arginine vasopressin receptor V3 and corticotropin-releasing factor receptor 1 messenger ribonucleic acids in the anterior pituitary of endotoxemic steers</article-title><source>Endocrine</source><year>2002</year><volume>18</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1385/ENDO:18:1:13</pub-id><pub-id pub-id-type="pmid">12166619</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Conarty</surname><given-names>DM</given-names></name><name><surname>Preston</surname><given-names>JA</given-names></name><name><surname>Plesnicher</surname><given-names>CL</given-names></name><name><surname>Dweik</surname><given-names>RA</given-names></name><name><surname>Erzurum</surname><given-names>SC</given-names></name><article-title>Human vascular endothelial cells express oxytocin receptors</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1210/en.140.3.1301</pub-id><pub-id pub-id-type="pmid">10067857</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Gutkowska</surname><given-names>J</given-names></name><name><surname>Jankowski</surname><given-names>M</given-names></name><name><surname>Mukaddam-Daher</surname><given-names>S</given-names></name><name><surname>McCann</surname><given-names>SM</given-names></name><article-title>Oxytocin is a cardiovascular hormone</article-title><source>Braz J Med Biol Res</source><year>2000</year><volume>33</volume><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">10829090</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Indrambarya</surname><given-names>T</given-names></name><name><surname>Boyd</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>McConechy</surname><given-names>M</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><article-title>Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R98</fpage><pub-id pub-id-type="doi">10.1186/cc7930</pub-id><pub-id pub-id-type="pmid">19549333</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Tsushima</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><article-title>Antidiuretic effects of ATP induced by microinjection into the hypothalamic supraoptic nucleus in water-loaded and ethanol-anesthetized rats</article-title><source>Jpn J Pharmacol</source><year>1994</year><volume>66</volume><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1254/jjp.66.445</pub-id><pub-id pub-id-type="pmid">7723221</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Bunstock</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><article-title>P2X receptors are differentially expressed on vasopressin- and oxytocin-containing neurons in the supraoptic and paraventricular nuclei of rat hypothalamus</article-title><source>Histochem Cell Biol</source><year>2009</year><volume>131</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s00418-008-0493-9</pub-id><pub-id pub-id-type="pmid">18787835</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Knott</surname><given-names>TK</given-names></name><name><surname>Velazquez-Marrero</surname><given-names>C</given-names></name><name><surname>Lemos</surname><given-names>JR</given-names></name><article-title>ATP elicits inward currents in isolated vasopressinergic neurohypophysial terminals via P2X2 and P2X3 receptors</article-title><source>Pflugers Arch</source><year>2005</year><volume>450</volume><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1007/s00424-005-1471-x</pub-id><pub-id pub-id-type="pmid">15988588</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Knott</surname><given-names>TK</given-names></name><name><surname>Marrero</surname><given-names>HG</given-names></name><name><surname>Custer</surname><given-names>EE</given-names></name><name><surname>Lemos</surname><given-names>JR</given-names></name><article-title>Endogenous ATP potentiates only vasopressin secretion from neurohypophysial terminals</article-title><source>J Cell Physiol</source><year>2008</year><volume>217</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1002/jcp.21485</pub-id><pub-id pub-id-type="pmid">18481265</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Vijayaraghavan</surname><given-names>S</given-names></name><name><surname>Sladek</surname><given-names>CD</given-names></name><article-title>ATP increases intracellular calcium in supraoptic neurons by activation of both P2X and P2Y purinergic receptors</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2007</year><volume>292</volume><fpage>R423</fpage><lpage>R431</lpage><pub-id pub-id-type="pmid">16973929</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Gomes</surname><given-names>DA</given-names></name><name><surname>Stevens</surname><given-names>W</given-names></name><article-title>Role of purinergic P2Y1 receptors in regulation of vasopressin and oxytocin secretion</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2009</year><volume>297</volume><fpage>R478</fpage><lpage>R484</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00163.2009</pub-id><pub-id pub-id-type="pmid">19515986</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Troadec</surname><given-names>JD</given-names></name><name><surname>Thirion</surname><given-names>S</given-names></name><name><surname>Nicaise</surname><given-names>G</given-names></name><name><surname>Lemos</surname><given-names>JR</given-names></name><name><surname>Dayanithi</surname><given-names>G</given-names></name><article-title>ATP-evoked increases in [Ca<sup>2+</sup>]<sub>i </sub>and peptide release from rat isolated neurohypophysial terminals via a P2X2 purinoceptor</article-title><source>J Physiol</source><year>1998</year><volume>511</volume><issue>Pt 1</issue><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">9679166</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Buller</surname><given-names>KM</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name><name><surname>Sibbald</surname><given-names>JR</given-names></name><name><surname>Day</surname><given-names>TA</given-names></name><article-title>Central noradrenergic neurons signal via ATP to elicit vasopressin responses to haemorrhage</article-title><source>Neuroscience</source><year>1996</year><volume>73</volume><fpage>637</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(96)00156-X</pub-id><pub-id pub-id-type="pmid">8809784</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Sperlagh</surname><given-names>B</given-names></name><name><surname>Mergl</surname><given-names>Z</given-names></name><name><surname>Juranyi</surname><given-names>Z</given-names></name><name><surname>Vizi</surname><given-names>ES</given-names></name><name><surname>Makara</surname><given-names>GB</given-names></name><article-title>Local regulation of vasopressin and oxytocin secretion by extracellular ATP in the isolated posterior lobe of the rat hypophysis</article-title><source>J Endocrinol</source><year>1999</year><volume>160</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1677/joe.0.1600343</pub-id><pub-id pub-id-type="pmid">10076181</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Kapoor</surname><given-names>JR</given-names></name><name><surname>Sladek</surname><given-names>CD</given-names></name><article-title>Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>8868</fpage><lpage>8875</lpage><pub-id pub-id-type="pmid">11102496</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Troadec</surname><given-names>JD</given-names></name><name><surname>Thirion</surname><given-names>S</given-names></name><article-title>Multifaceted purinergic regulation of stimulussecretion coupling in the neurohypophysis</article-title><source>Neuro Endocrinol Lett</source><year>2002</year><volume>23</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">12195224</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Burnstock</surname><given-names>G</given-names></name><article-title>P2X5 receptors are expressed on neurons containing arginine vasopressin and nitric oxide synthase in the rat hypothalamus</article-title><source>Brain Res</source><year>2006</year><volume>1099</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.04.126</pub-id><pub-id pub-id-type="pmid">16765918</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Sladek</surname><given-names>CD</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><article-title>Regulation of vasopressin release by co-released neurotransmitters: mechanisms of purinergic and adrenergic synergism</article-title><source>Prog Brain Res</source><year>2008</year><volume>170</volume><fpage>93</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">18655875</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Gomes</surname><given-names>DA</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Stevens</surname><given-names>W</given-names></name><name><surname>Sladek</surname><given-names>CD</given-names></name><article-title>Sustained stimulation of vasopressin and oxytocin release by ATP and phenylephrine requires recruitment of desensitization-resistant P2X purinergic receptors</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2009</year><volume>297</volume><fpage>R940</fpage><lpage>R949</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00358.2009</pub-id><pub-id pub-id-type="pmid">19625689</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Espallergues</surname><given-names>J</given-names></name><name><surname>Solovieva</surname><given-names>O</given-names></name><name><surname>Techer</surname><given-names>V</given-names></name><name><surname>Bauer</surname><given-names>K</given-names></name><name><surname>Alonso</surname><given-names>G</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Hussy</surname><given-names>N</given-names></name><article-title>Synergistic activation of astrocytes by ATP and norepinephrine in the rat supraoptic nucleus</article-title><source>Neuroscience</source><year>2007</year><volume>148</volume><fpage>712</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.03.043</pub-id><pub-id pub-id-type="pmid">17693027</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Sladek</surname><given-names>CD</given-names></name><article-title>Does conversion of ATP to adenosine terminate ATP-stimulated vasopressin release from hypothalamo-neurohypophyseal explants?</article-title><source>Brain Res</source><year>2005</year><volume>1047</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2005.04.025</pub-id><pub-id pub-id-type="pmid">15893296</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Cha</surname><given-names>SH</given-names></name><name><surname>Sekine</surname><given-names>T</given-names></name><name><surname>Endou</surname><given-names>H</given-names></name><article-title>P2 purinoceptor localization along rat nephron and evidence suggesting existence of subtypes P2Y1 and P2Y2</article-title><source>Am J Physiol</source><year>1998</year><volume>274</volume><issue>6 Pt 2</issue><fpage>F1006</fpage><lpage>F1014</lpage><pub-id pub-id-type="pmid">9841490</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Wildman</surname><given-names>SS</given-names></name><name><surname>Boone</surname><given-names>M</given-names></name><name><surname>Peppiatt-Wildman</surname><given-names>CM</given-names></name><name><surname>Contreras-Sanz</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>BF</given-names></name><name><surname>Shirley</surname><given-names>DG</given-names></name><name><surname>Deen</surname><given-names>PM</given-names></name><name><surname>Unwin</surname><given-names>RJ</given-names></name><article-title>Nucleotides downregulate aquaporin 2 via activation of apical P2 receptors</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><fpage>1480</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008070686</pub-id><pub-id pub-id-type="pmid">19423692</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Rieg</surname><given-names>T</given-names></name><name><surname>Bundey</surname><given-names>RA</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Deschenes</surname><given-names>G</given-names></name><name><surname>Junger</surname><given-names>W</given-names></name><name><surname>Insel</surname><given-names>PA</given-names></name><name><surname>Vallon</surname><given-names>V</given-names></name><article-title>Mice lacking P2Y2 receptors have salt-resistant hypertension and facilitated renal Na<sup>+ </sup>and water reabsorption</article-title><source>FASEB J</source><year>2007</year><volume>21</volume><fpage>3717</fpage><lpage>3726</lpage><pub-id pub-id-type="doi">10.1096/fj.07-8807com</pub-id><pub-id pub-id-type="pmid">17575258</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Zenteno-Savin</surname><given-names>T</given-names></name><name><surname>Sada-Ovalle</surname><given-names>I</given-names></name><name><surname>Ceballos</surname><given-names>G</given-names></name><name><surname>Rubio</surname><given-names>R</given-names></name><article-title>Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>410</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(00)00853-0</pub-id><pub-id pub-id-type="pmid">11134652</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>MF</given-names></name><name><surname>Brackett</surname><given-names>DJ</given-names></name><name><surname>Tompkins</surname><given-names>P</given-names></name><name><surname>Benjamin</surname><given-names>B</given-names></name><name><surname>Archer</surname><given-names>LT</given-names></name><name><surname>Hinshaw</surname><given-names>LB</given-names></name><article-title>Elevated plasma vasopressin concentrations during endotoxin and <italic>E. coli </italic>shock</article-title><source>Adv Shock Res</source><year>1981</year><volume>6</volume><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">6760706</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Levin</surname><given-names>HR</given-names></name><name><surname>Gallant</surname><given-names>EM</given-names></name><name><surname>Ashton</surname><given-names>RC</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>D'Alessandro</surname><given-names>D</given-names></name><name><surname>Oz</surname><given-names>MC</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name><article-title>Vasopressin deficiency contributes to the vasodilation of septic shock</article-title><source>Circulation</source><year>1997</year><volume>95</volume><fpage>1122</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">9054839</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Levin</surname><given-names>HR</given-names></name><name><surname>Gallant</surname><given-names>EM</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>D'Alessandro</surname><given-names>D</given-names></name><name><surname>Oz</surname><given-names>MC</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name><article-title>Vasopressin pressor hypersensitivity in vasodilatory septic shock</article-title><source>Crit Care Med</source><year>1997</year><volume>25</volume><fpage>1279</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1097/00003246-199708000-00012</pub-id><pub-id pub-id-type="pmid">9267938</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Paillard</surname><given-names>M</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Gajdos</surname><given-names>P</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><article-title>Circulating vasopressin levels in septic shock</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1752</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000063046.82359.4A</pub-id><pub-id pub-id-type="pmid">12794416</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Carlier</surname><given-names>R</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Feydy</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Paillard</surname><given-names>M</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Gajdos</surname><given-names>P</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><article-title>Depletion of neurohypophyseal content of vasopressin in septic shock</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1097/00003246-200203000-00001</pub-id><pub-id pub-id-type="pmid">11990905</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Hebert</surname><given-names>PC</given-names></name><name><surname>Cooper</surname><given-names>DJ</given-names></name><name><surname>Holmes</surname><given-names>CL</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name><name><surname>Storms</surname><given-names>MM</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Presneill</surname><given-names>JJ</given-names></name><name><surname>Ayers</surname><given-names>D</given-names></name><article-title>Vasopressin versus norepinephrine infusion in patients with septic shock</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>877</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa067373</pub-id><pub-id pub-id-type="pmid">18305265</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Jochberger</surname><given-names>S</given-names></name><name><surname>Dorler</surname><given-names>J</given-names></name><name><surname>Luckner</surname><given-names>G</given-names></name><name><surname>Mayr</surname><given-names>VD</given-names></name><name><surname>Wenzel</surname><given-names>V</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><name><surname>Dunser</surname><given-names>MW</given-names></name><article-title>The vasopressin and copeptin response to infection, severe sepsis, and septic shock</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181957532</pub-id><pub-id pub-id-type="pmid">19114902</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Carnio</surname><given-names>EC</given-names></name><name><surname>Moreto</surname><given-names>V</given-names></name><name><surname>Giusti-Paiva</surname><given-names>A</given-names></name><name><surname>Antunes-Rodrigues</surname><given-names>J</given-names></name><article-title>Neuro-immuneendocrine mechanisms during septic shock: role for nitric oxide in vasopressin and oxytocin release</article-title><source>Endocr Metab Immune Disord Drug Targets</source><year>2006</year><volume>6</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">16787287</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Correa</surname><given-names>PB</given-names></name><name><surname>Pancoto</surname><given-names>JA</given-names></name><name><surname>de Oliveira-Pelegrin</surname><given-names>GR</given-names></name><name><surname>Carnio</surname><given-names>EC</given-names></name><name><surname>Rocha</surname><given-names>MJ</given-names></name><article-title>Participation of iNOS-derived NO in hypothalamic activation and vasopressin release during polymicrobial sepsis</article-title><source>J Neuroimmunol</source><year>2007</year><volume>183</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.10.021</pub-id><pub-id pub-id-type="pmid">17173980</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Moreto</surname><given-names>V</given-names></name><name><surname>Stabile</surname><given-names>AM</given-names></name><name><surname>Antunes-Rodrigues</surname><given-names>J</given-names></name><name><surname>Carnio</surname><given-names>EC</given-names></name><article-title>Role of hemeoxygenase pathway on vasopressin deficiency during endotoxemic shock-like conditions</article-title><source>Shock</source><year>2006</year><volume>26</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000230301.86139.6a</pub-id><pub-id pub-id-type="pmid">17047517</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Muller</surname><given-names>B</given-names></name><name><surname>Struck</surname><given-names>J</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name><name><surname>Redl</surname><given-names>H</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><article-title>Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock</article-title><source>Shock</source><year>2007</year><volume>28</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1097/SHK.0b013e318033e5da</pub-id><pub-id pub-id-type="pmid">17515850</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Muller</surname><given-names>B</given-names></name><name><surname>Morgenthaler</surname><given-names>N</given-names></name><name><surname>Stolz</surname><given-names>D</given-names></name><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><article-title>Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections</article-title><source>Eur J Clin Invest</source><year>2007</year><volume>37</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2007.01762.x</pub-id><pub-id pub-id-type="pmid">17217381</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Jochberger</surname><given-names>S</given-names></name><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Mayr</surname><given-names>VD</given-names></name><name><surname>Luckner</surname><given-names>G</given-names></name><name><surname>Wenzel</surname><given-names>V</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Schwarz</surname><given-names>S</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><name><surname>Friesenecker</surname><given-names>BE</given-names></name><name><surname>Dunser</surname><given-names>MW</given-names></name><article-title>Copeptin and arginine vasopressin concentrations in critically ill patients</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>4381</fpage><lpage>4386</lpage><pub-id pub-id-type="doi">10.1210/jc.2005-2830</pub-id><pub-id pub-id-type="pmid">16940457</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Jochberger</surname><given-names>S</given-names></name><name><surname>Mayr</surname><given-names>VD</given-names></name><name><surname>Luckner</surname><given-names>G</given-names></name><name><surname>Wenzel</surname><given-names>V</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Schmid</surname><given-names>S</given-names></name><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Pajk</surname><given-names>W</given-names></name><name><surname>Hasibeder</surname><given-names>W</given-names></name><name><surname>Friesenecker</surname><given-names>B</given-names></name><name><surname>Mayr</surname><given-names>AG</given-names></name><name><surname>Dunser</surname><given-names>MW</given-names></name><article-title>Serum vasopressin concentrations in critically ill patients</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><fpage>293</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000198528.56397.4F</pub-id><pub-id pub-id-type="pmid">16424705</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>IY</given-names></name><name><surname>Ma</surname><given-names>HP</given-names></name><name><surname>Lin</surname><given-names>AC</given-names></name><name><surname>Chong</surname><given-names>CF</given-names></name><name><surname>Lin</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name><article-title>Low plasma vasopressin/norepinephrine ratio predicts septic shock</article-title><source>Am J Emerg Med</source><year>2005</year><volume>23</volume><fpage>718</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2005.02.055</pub-id><pub-id pub-id-type="pmid">16182977</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Luckner</surname><given-names>G</given-names></name><name><surname>Dunser</surname><given-names>MW</given-names></name><name><surname>Jochberger</surname><given-names>S</given-names></name><name><surname>Mayr</surname><given-names>VD</given-names></name><name><surname>Wenzel</surname><given-names>V</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Schmid</surname><given-names>S</given-names></name><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Pajk</surname><given-names>W</given-names></name><name><surname>Hasibeder</surname><given-names>W</given-names></name><name><surname>Mayr</surname><given-names>AG</given-names></name><name><surname>Friesenecker</surname><given-names>B</given-names></name><article-title>Arginine vasopressin in 316 patients with advanced vasodilatory shock</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>2659</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000186749.34028.40</pub-id><pub-id pub-id-type="pmid">16276194</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Luckner</surname><given-names>G</given-names></name><name><surname>Mayr</surname><given-names>VD</given-names></name><name><surname>Jochberger</surname><given-names>S</given-names></name><name><surname>Wenzel</surname><given-names>V</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><name><surname>Dunser</surname><given-names>MW</given-names></name><article-title>Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>2280</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000281853.50661.23</pub-id><pub-id pub-id-type="pmid">17944015</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Lodha</surname><given-names>R</given-names></name><name><surname>Vivekanandhan</surname><given-names>S</given-names></name><name><surname>Sarthi</surname><given-names>M</given-names></name><name><surname>Kabra</surname><given-names>SK</given-names></name><article-title>Serial circulating vasopressin levels in children with septic shock</article-title><source>Pediatr Crit Care Med</source><year>2006</year><volume>7</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1097/01.PCC.0000216414.00362.81</pub-id><pub-id pub-id-type="pmid">16575349</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Scharte</surname><given-names>M</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><article-title>Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><fpage>1756</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1097/00003246-200109000-00017</pub-id><pub-id pub-id-type="pmid">11546979</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Nakajima</surname><given-names>Y</given-names></name><name><surname>Baudry</surname><given-names>N</given-names></name><name><surname>Duranteau</surname><given-names>J</given-names></name><name><surname>Vicaut</surname><given-names>E</given-names></name><article-title>Effects of vasopressin, norepinephrine, and L-arginine on intestinal microcirculation in endotoxemia</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><fpage>1752</fpage><lpage>1757</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000218812.73741.6C</pub-id><pub-id pub-id-type="pmid">16625119</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Maier</surname><given-names>S</given-names></name><name><surname>Dunser</surname><given-names>MW</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><name><surname>Hausdorfer</surname><given-names>H</given-names></name><name><surname>Brandner</surname><given-names>J</given-names></name><name><surname>Torgersen</surname><given-names>C</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Friesenecker</surname><given-names>B</given-names></name><name><surname>Iannetti</surname><given-names>C</given-names></name><name><surname>Pajik</surname><given-names>W</given-names></name><article-title>Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/s00134-005-2858-z</pub-id><pub-id pub-id-type="pmid">16328220</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Leone</surname><given-names>M</given-names></name><name><surname>Boyle</surname><given-names>WA</given-names></name><article-title>Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><fpage>1126</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000206466.56669.BE</pub-id><pub-id pub-id-type="pmid">16484914</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>WG</given-names></name><article-title>The effect of vasopressin on organ blood flow in an endotoxin-induced rabbit shock model</article-title><source>J Invest Surg</source><year>2006</year><volume>19</volume><fpage>361</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1080/08941930600985702</pub-id><pub-id pub-id-type="pmid">17101605</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name><surname>Dubois</surname><given-names>MJ</given-names></name><name><surname>De Backer</surname><given-names>D</given-names></name><name><surname>Creteur</surname><given-names>J</given-names></name><name><surname>Anane</surname><given-names>S</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><article-title>Effect of vasopressin on sublingual microcirculation in a patient with distributive shock</article-title><source>Intensive Care Med</source><year>2003</year><volume>29</volume><fpage>1020</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">12736775</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name><surname>Kienbaum</surname><given-names>P</given-names></name><name><surname>Prante</surname><given-names>C</given-names></name><name><surname>Lehmann</surname><given-names>N</given-names></name><name><surname>Sander</surname><given-names>A</given-names></name><name><surname>Jalowy</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><article-title>Alterations in forearm vascular reactivity in patients with septic shock</article-title><source>Anaesthesia</source><year>2008</year><volume>63</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.2007.05286.x</pub-id><pub-id pub-id-type="pmid">18211441</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>JA</given-names></name><article-title>Vasopressin in vasodilatory and septic shock</article-title><source>Curr Opin Crit Care</source><year>2007</year><volume>13</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1097/MCC.0b013e328263885e</pub-id><pub-id pub-id-type="pmid">17599007</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><name><surname>Dunser</surname><given-names>MW</given-names></name><name><surname>Mayr</surname><given-names>AJ</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Ritsch</surname><given-names>N</given-names></name><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Pajk</surname><given-names>W</given-names></name><name><surname>Luckner</surname><given-names>G</given-names></name><name><surname>Mutz</surname><given-names>NJ</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><article-title>The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis</article-title><source>Anesth Analg</source><year>2001</year><volume>93</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11429329</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><name><surname>Dunser</surname><given-names>MW</given-names></name><name><surname>Mayr</surname><given-names>AJ</given-names></name><name><surname>Stallinger</surname><given-names>A</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Ritsch</surname><given-names>N</given-names></name><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Pajk</surname><given-names>W</given-names></name><name><surname>Mutz</surname><given-names>NJ</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><article-title>Cardiac performance during vasopressin infusion in postcardiotomy shock</article-title><source>Intensive Care Med</source><year>2002</year><volume>28</volume><fpage>746</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1007/s00134-002-1265-y</pub-id><pub-id pub-id-type="pmid">12107681</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><name><surname>Dunser</surname><given-names>MW</given-names></name><name><surname>Mayr</surname><given-names>AJ</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Sumann</surname><given-names>G</given-names></name><name><surname>Pajk</surname><given-names>W</given-names></name><name><surname>Friesenecker</surname><given-names>B</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><article-title>Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>2313</fpage><lpage>2319</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000066692.71008.BB</pub-id><pub-id pub-id-type="pmid">12732600</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>CL</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Chittock</surname><given-names>DR</given-names></name><name><surname>Lehman</surname><given-names>T</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><article-title>The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series</article-title><source>Intensive Care Med</source><year>2001</year><volume>27</volume><fpage>1416</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1007/s001340101014</pub-id><pub-id pub-id-type="pmid">11511958</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><name><surname>Malay</surname><given-names>MB</given-names></name><name><surname>Ashton</surname><given-names>RC</given-names></name><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Townsend</surname><given-names>RN</given-names></name><article-title>Low-dose vasopressin in the treatment of vasodilatory septic shock</article-title><source>J Trauma</source><year>1999</year><volume>47</volume><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1097/00005373-199910000-00014</pub-id><pub-id pub-id-type="pmid">10528604</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>BM</given-names></name><name><surname>Chittock</surname><given-names>DR</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><article-title>Beneficial effects of short-term vasopressin infusion during severe septic shock</article-title><source>Anesthesiology</source><year>2002</year><volume>96</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1097/00000542-200203000-00011</pub-id><pub-id pub-id-type="pmid">11873030</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><name><surname>Hiltebrand</surname><given-names>LB</given-names></name><name><surname>Krejci</surname><given-names>V</given-names></name><name><surname>Jakob</surname><given-names>SM</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name><name><surname>Sigurdsson</surname><given-names>GH</given-names></name><article-title>Effects of vasopressin on microcirculatory blood flow in the gastrointestinal tract in anesthetized pigs in septic shock</article-title><source>Anesthesiology</source><year>2007</year><volume>106</volume><fpage>1156</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1097/01.anes.0000267599.02140.86</pub-id><pub-id pub-id-type="pmid">17525591</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><name><surname>Dunser</surname><given-names>MW</given-names></name><name><surname>Mayr</surname><given-names>AJ</given-names></name><name><surname>Tur</surname><given-names>A</given-names></name><name><surname>Pajk</surname><given-names>W</given-names></name><name><surname>Barbara</surname><given-names>F</given-names></name><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><article-title>Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1394</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000059722.94182.79</pub-id><pub-id pub-id-type="pmid">12771608</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><name><surname>Aninat</surname><given-names>C</given-names></name><name><surname>Seguin</surname><given-names>P</given-names></name><name><surname>Descheemaeker</surname><given-names>PN</given-names></name><name><surname>Morel</surname><given-names>F</given-names></name><name><surname>Malledant</surname><given-names>Y</given-names></name><name><surname>Guillouzo</surname><given-names>A</given-names></name><article-title>Catecholamines induce an inflammatory response in human hepatocytes</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>848</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1097/CCM.0B013E31816532BE</pub-id><pub-id pub-id-type="pmid">18431272</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><collab>American College of Chest Physicians/Society of Critical Care Medicine</collab><article-title>Consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis</article-title><source>Crit Care Med</source><year>1992</year><volume>20</volume><fpage>864</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1097/00003246-199206000-00025</pub-id><pub-id pub-id-type="pmid">1597042</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name><name><surname>Sprung</surname><given-names>CL</given-names></name><article-title>The ACCP-SCCM consensus conference on sepsis and organ failure</article-title><source>Chest</source><year>1992</year><volume>101</volume><fpage>1481</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1378/chest.101.6.1481</pub-id><pub-id pub-id-type="pmid">1600757</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Cerra</surname><given-names>FB</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Fein</surname><given-names>AM</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Schein</surname><given-names>RM</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name><article-title>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine</article-title><source>Chest</source><year>1992</year><volume>101</volume><fpage>1644</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1378/chest.101.6.1644</pub-id><pub-id pub-id-type="pmid">1303622</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Carlet</surname><given-names>JM</given-names></name><name><surname>Bion</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>MM</given-names></name><name><surname>Jaeschke</surname><given-names>R</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name><name><surname>Beale</surname><given-names>R</given-names></name><name><surname>Calandra</surname><given-names>T</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Gerlach</surname><given-names>H</given-names></name><article-title>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>296</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000298158.12101.41</pub-id><pub-id pub-id-type="pmid">18158437</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Keh</surname><given-names>D</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Freivogel</surname><given-names>K</given-names></name><name><surname>Weiss</surname><given-names>YG</given-names></name><name><surname>Benbenishty</surname><given-names>J</given-names></name><name><surname>Kalenka</surname><given-names>A</given-names></name><name><surname>Forst</surname><given-names>H</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Cuthbertson</surname><given-names>BH</given-names></name><article-title>Hydrocortisone therapy for patients with septic shock</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>111</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa071366</pub-id><pub-id pub-id-type="pmid">18184957</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><name><surname>Rivers</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>B</given-names></name><name><surname>Havstad</surname><given-names>S</given-names></name><name><surname>Ressler</surname><given-names>J</given-names></name><name><surname>Muzzin</surname><given-names>A</given-names></name><name><surname>Knoblich</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Tomlanovich</surname><given-names>M</given-names></name><article-title>Early goal-directed therapy in the treatment of severe sepsis and septic shock</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>1368</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa010307</pub-id><pub-id pub-id-type="pmid">11794169</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>LG</given-names></name><name><surname>Oyen</surname><given-names>LJ</given-names></name><name><surname>Taner</surname><given-names>CB</given-names></name><name><surname>Cullinane</surname><given-names>DC</given-names></name><name><surname>Baird</surname><given-names>TK</given-names></name><name><surname>Cha</surname><given-names>SS</given-names></name><name><surname>Sawyer</surname><given-names>MD</given-names></name><article-title>Fixeddose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock</article-title><source>Pharmacotherapy</source><year>2004</year><volume>24</volume><fpage>1002</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1592/phco.24.11.1002.36139</pub-id><pub-id pub-id-type="pmid">15338849</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Cooper</surname><given-names>DJ</given-names></name><name><surname>Hebert</surname><given-names>PC</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Holmes</surname><given-names>CL</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name><name><surname>Storms</surname><given-names>MM</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Presneill</surname><given-names>JJ</given-names></name><article-title>Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181961ace</pub-id><pub-id pub-id-type="pmid">19237882</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><name><surname>Rabadan-Diehl</surname><given-names>C</given-names></name><name><surname>Aguilera</surname><given-names>G</given-names></name><article-title>Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C</article-title><source>Endocrinology</source><year>1998</year><volume>139</volume><fpage>3220</fpage><lpage>3226</lpage><pub-id pub-id-type="doi">10.1210/en.139.7.3220</pub-id><pub-id pub-id-type="pmid">9645696</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Erren</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia</article-title><source>Shock</source><year>2007</year><volume>27</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000235140.97903.90</pub-id><pub-id pub-id-type="pmid">17304109</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><name><surname>Lauand</surname><given-names>F</given-names></name><name><surname>Ruginsk</surname><given-names>SG</given-names></name><name><surname>Rodrigues</surname><given-names>HL</given-names></name><name><surname>Reis</surname><given-names>WL</given-names></name><name><surname>de Castro</surname><given-names>M</given-names></name><name><surname>Elias</surname><given-names>LL</given-names></name><name><surname>Antunes-Rodrigues</surname><given-names>J</given-names></name><article-title>Glucocorticoid modulation of atrial natriuretic peptide, oxytocin, vasopressin and Fos expression in response to osmotic, angiotensinergic and cholinergic stimulation</article-title><source>Neuroscience</source><year>2007</year><volume>147</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.04.021</pub-id><pub-id pub-id-type="pmid">17524563</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><name><surname>Pietranera</surname><given-names>L</given-names></name><name><surname>Saravia</surname><given-names>F</given-names></name><name><surname>Roig</surname><given-names>P</given-names></name><name><surname>Lima</surname><given-names>A</given-names></name><name><surname>De Nicola</surname><given-names>AF</given-names></name><article-title>Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats</article-title><source>Neuroendocrinology</source><year>2004</year><volume>80</volume><fpage>100</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1159/000081314</pub-id><pub-id pub-id-type="pmid">15475662</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><name><surname>Aguilera</surname><given-names>G</given-names></name><name><surname>Rabadan-Diehl</surname><given-names>C</given-names></name><article-title>Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation</article-title><source>Regul Pept</source><year>2000</year><volume>96</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0167-0115(00)00196-8</pub-id><pub-id pub-id-type="pmid">11102648</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><name><surname>Tanoue</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Oshikawa</surname><given-names>S</given-names></name><name><surname>Kitagawa</surname><given-names>Y</given-names></name><name><surname>Koshimizu</surname><given-names>TA</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name><article-title>The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions</article-title><source>J Clin Invest</source><year>2004</year><volume>113</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">14722621</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><name><surname>Annane</surname><given-names>D</given-names></name><article-title>Vasopressin plus corticosteroids: the shock duo!</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>1126</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31819879c1</pub-id><pub-id pub-id-type="pmid">19237927</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><name><surname>Dunser</surname><given-names>MW</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><name><surname>Wenzel</surname><given-names>V</given-names></name><article-title>Vasopressin in septic shock</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2736</fpage><comment>author reply 7-8</comment><pub-id pub-id-type="pmid">18572442</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Freise</surname><given-names>H</given-names></name><name><surname>Kehrel</surname><given-names>BE</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Sielenkamper</surname><given-names>AW</given-names></name><article-title>Arginine vasopressin compromises gut mucosal microcirculation in septic rats</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000104201.62736.12</pub-id><pub-id pub-id-type="pmid">14707579</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><name><surname>Martikainen</surname><given-names>TJ</given-names></name><name><surname>Tenhunen</surname><given-names>JJ</given-names></name><name><surname>Uusaro</surname><given-names>A</given-names></name><name><surname>Ruokonen</surname><given-names>E</given-names></name><article-title>The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock</article-title><source>Anesth Analg</source><year>2003</year><volume>97</volume><fpage>1756</fpage><lpage>1763</lpage><pub-id pub-id-type="doi">10.1213/01.ANE.0000087039.60041.2E</pub-id><pub-id pub-id-type="pmid">14633555</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><name><surname>Klinzing</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Bredle</surname><given-names>DL</given-names></name><name><surname>Meier-Hellmann</surname><given-names>A</given-names></name><article-title>High-dose vasopressin is not superior to norepinephrine in septic shock</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>2646</fpage><lpage>2650</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000094260.05266.F4</pub-id><pub-id pub-id-type="pmid">14605537</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><name><surname>Leone</surname><given-names>M</given-names></name><name><surname>Albanese</surname><given-names>J</given-names></name><name><surname>Delmas</surname><given-names>A</given-names></name><name><surname>Chaabane</surname><given-names>W</given-names></name><name><surname>Garnier</surname><given-names>F</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><article-title>Terlipressin in catecholamine-resistant septic shock patients</article-title><source>Shock</source><year>2004</year><volume>22</volume><fpage>314</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000136097.42048.bd</pub-id><pub-id pub-id-type="pmid">15377885</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><name><surname>Leone</surname><given-names>M</given-names></name><name><surname>Boutiere-Albanese</surname><given-names>B</given-names></name><name><surname>Valette</surname><given-names>S</given-names></name><name><surname>Camoin-Jau</surname><given-names>L</given-names></name><name><surname>Barrau</surname><given-names>K</given-names></name><name><surname>Albanese</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Dignat-George</surname><given-names>F</given-names></name><article-title>Cell adhesion molecules as a marker reflecting the reduction of endothelial activation induced by glucocorticoids</article-title><source>Shock</source><year>2004</year><volume>21</volume><fpage>311</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1097/00024382-200404000-00004</pub-id><pub-id pub-id-type="pmid">15179130</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><name><surname>O'Brien</surname><given-names>A</given-names></name><name><surname>Clapp</surname><given-names>L</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><article-title>Terlipressin for norepinephrine-resistant septic shock</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1209</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)08225-9</pub-id><pub-id pub-id-type="pmid">11955542</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><name><surname>Albanese</surname><given-names>J</given-names></name><name><surname>Leone</surname><given-names>M</given-names></name><name><surname>Delmas</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><article-title>Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>1897</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000178182.37639.D6</pub-id><pub-id pub-id-type="pmid">16148457</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><name><surname>Asfar</surname><given-names>P</given-names></name><name><surname>Pierrot</surname><given-names>M</given-names></name><name><surname>Veal</surname><given-names>N</given-names></name><name><surname>Moal</surname><given-names>F</given-names></name><name><surname>Oberti</surname><given-names>F</given-names></name><name><surname>Croquet</surname><given-names>V</given-names></name><name><surname>Douay</surname><given-names>O</given-names></name><name><surname>Gallois</surname><given-names>Y</given-names></name><name><surname>Saumet</surname><given-names>JL</given-names></name><name><surname>Alquier</surname><given-names>P</given-names></name><name><surname>Cales</surname><given-names>P</given-names></name><article-title>Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1097/00003246-200301000-00033</pub-id><pub-id pub-id-type="pmid">12545018</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><name><surname>Asfar</surname><given-names>P</given-names></name><name><surname>Hauser</surname><given-names>B</given-names></name><name><surname>Ivanyi</surname><given-names>Z</given-names></name><name><surname>Ehrmann</surname><given-names>U</given-names></name><name><surname>Kick</surname><given-names>J</given-names></name><name><surname>Albicini</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>J</given-names></name><name><surname>Wachter</surname><given-names>U</given-names></name><name><surname>Bruckner</surname><given-names>UB</given-names></name><name><surname>Radermacher</surname><given-names>P</given-names></name><name><surname>Bracht</surname><given-names>H</given-names></name><article-title>Low-dose terlipressin during longterm hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>373</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000152253.45901.FB</pub-id><pub-id pub-id-type="pmid">15699842</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Rocco</surname><given-names>M</given-names></name><name><surname>Conti</surname><given-names>G</given-names></name><name><surname>Orecchioni</surname><given-names>A</given-names></name><name><surname>De Gaetano</surname><given-names>A</given-names></name><name><surname>Cortese</surname><given-names>G</given-names></name><name><surname>Coluzzi</surname><given-names>F</given-names></name><name><surname>Vernaglione</surname><given-names>E</given-names></name><name><surname>Pelaia</surname><given-names>P</given-names></name><name><surname>Pietropaoli</surname><given-names>P</given-names></name><article-title>Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1007/s00134-003-2094-3</pub-id><pub-id pub-id-type="pmid">14673520</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Stubbe</surname><given-names>H</given-names></name><name><surname>Sielenkamper</surname><given-names>AW</given-names></name><name><surname>Ball</surname><given-names>C</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Borgulya</surname><given-names>R</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><article-title>Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1502</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000063042.15272.84</pub-id><pub-id pub-id-type="pmid">12771625</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Stubbe</surname><given-names>H</given-names></name><name><surname>Sielenkamper</surname><given-names>AW</given-names></name><name><surname>Borgulya</surname><given-names>R</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Ball</surname><given-names>C</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><article-title>Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport</article-title><source>Intensive Care Med</source><year>2003</year><volume>29</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">12594590</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><name><surname>Pesaturo</surname><given-names>AB</given-names></name><name><surname>Jennings</surname><given-names>HR</given-names></name><name><surname>Voils</surname><given-names>SA</given-names></name><article-title>Terlipressin: vasopressin analog and novel drug for septic shock</article-title><source>Ann Pharmacother</source><year>2006</year><volume>40</volume><fpage>2170</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1345/aph.1H373</pub-id><pub-id pub-id-type="pmid">17148649</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Dunser</surname><given-names>M</given-names></name><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Pietropaoli</surname><given-names>P</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study</article-title><source>Br J Anaesth</source><year>2008</year><volume>100</volume><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1093/bja/aen017</pub-id><pub-id pub-id-type="pmid">18308741</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis</article-title><source>Intensive Care Med</source><year>2008</year><volume>34</volume><fpage>821</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1007/s00134-007-0946-y</pub-id><pub-id pub-id-type="pmid">18066524</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><name><surname>Bernadich</surname><given-names>C</given-names></name><name><surname>Bandi</surname><given-names>JC</given-names></name><name><surname>Melin</surname><given-names>P</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><article-title>Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension</article-title><source>Hepatology</source><year>1998</year><volume>27</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1002/hep.510270206</pub-id><pub-id pub-id-type="pmid">9462630</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><name><surname>Forsling</surname><given-names>ML</given-names></name><name><surname>Aziz</surname><given-names>LA</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>R</given-names></name><name><surname>Donovan</surname><given-names>B</given-names></name><article-title>Conversion of triglycylvasopressin to lysine-vasopressin in man</article-title><source>J Endocrinol</source><year>1980</year><volume>85</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1677/joe.0.0850237</pub-id><pub-id pub-id-type="pmid">7400711</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><name><surname>Fabian</surname><given-names>M</given-names></name><name><surname>Forsling</surname><given-names>ML</given-names></name><name><surname>Jones</surname><given-names>JJ</given-names></name><name><surname>Pryor</surname><given-names>JS</given-names></name><article-title>The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability</article-title><source>J Physiol</source><year>1969</year><volume>204</volume><fpage>653</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">5824107</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><name><surname>Nilsson</surname><given-names>G</given-names></name><name><surname>Lindblom</surname><given-names>P</given-names></name><name><surname>Ohlin</surname><given-names>M</given-names></name><name><surname>Berling</surname><given-names>R</given-names></name><name><surname>Vernersson</surname><given-names>E</given-names></name><article-title>Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers</article-title><source>Drugs Exp Clin Res</source><year>1990</year><volume>16</volume><fpage>307</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">2086166</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Weksler</surname><given-names>N</given-names></name><name><surname>Borer</surname><given-names>A</given-names></name><name><surname>Koyfman</surname><given-names>L</given-names></name><name><surname>Kesslin</surname><given-names>J</given-names></name><name><surname>Gurman</surname><given-names>GM</given-names></name><article-title>Terlipressin facilitates transport of septic patients treated with norepinephrine</article-title><source>Isr Med Assoc J</source><year>2006</year><volume>8</volume><fpage>691</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">17125115</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><name><surname>Solanki</surname><given-names>P</given-names></name><name><surname>Chawla</surname><given-names>A</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Sarin</surname><given-names>SK</given-names></name><article-title>Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebocontrolled clinical trial</article-title><source>J Gastroenterol Hepatol</source><year>2003</year><volume>18</volume><fpage>152</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1746.2003.02934.x</pub-id><pub-id pub-id-type="pmid">12542598</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Boyer</surname><given-names>T</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name><surname>Regenstein</surname><given-names>F</given-names></name><name><surname>Rossaro</surname><given-names>L</given-names></name><name><surname>Appenrodt</surname><given-names>B</given-names></name><name><surname>Blei</surname><given-names>A</given-names></name><name><surname>Gulberg</surname><given-names>V</given-names></name><name><surname>Sigal</surname><given-names>S</given-names></name><name><surname>Teuber</surname><given-names>P</given-names></name><article-title>A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome</article-title><source>Gastroenterology</source><year>2008</year><volume>134</volume><fpage>1360</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.02.014</pub-id><pub-id pub-id-type="pmid">18471513</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><name><surname>Martin-Llahi</surname><given-names>M</given-names></name><name><surname>Pepin</surname><given-names>MN</given-names></name><name><surname>Guevara</surname><given-names>M</given-names></name><name><surname>Diaz</surname><given-names>F</given-names></name><name><surname>Torre</surname><given-names>A</given-names></name><name><surname>Monescillo</surname><given-names>A</given-names></name><name><surname>Soriano</surname><given-names>G</given-names></name><name><surname>Terra</surname><given-names>C</given-names></name><name><surname>Fabrega</surname><given-names>E</given-names></name><name><surname>Arroyo</surname><given-names>V</given-names></name><name><surname>Rhodes</surname><given-names>J</given-names></name><name><surname>Gines</surname><given-names>P</given-names></name><article-title>Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study</article-title><source>Gastroenterology</source><year>2008</year><volume>134</volume><fpage>1352</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.02.024</pub-id><pub-id pub-id-type="pmid">18471512</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Ayers</surname><given-names>D</given-names></name><name><surname>Storms</surname><given-names>MM</given-names></name><name><surname>Holmes</surname><given-names>CL</given-names></name><name><surname>Hebert</surname><given-names>PC</given-names></name><name><surname>Cooper</surname><given-names>DJ</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Presneill</surname><given-names>JJ</given-names></name><article-title>The effects of vasopressin on acute kidney injury in septic shock</article-title><source>Intensive Care Medicine</source><year>2009</year><volume>36</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">19841897</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Orecchioni</surname><given-names>A</given-names></name><name><surname>Cecchini</surname><given-names>V</given-names></name><name><surname>Bachetoni</surname><given-names>A</given-names></name><name><surname>D'Alessandro</surname><given-names>M</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Pietropaoli</surname><given-names>P</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R130</fpage><pub-id pub-id-type="doi">10.1186/cc7990</pub-id><pub-id pub-id-type="pmid">19664253</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Kohler</surname><given-names>G</given-names></name><name><surname>Spiegel</surname><given-names>HU</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Moll</surname><given-names>K</given-names></name><name><surname>Schlack</surname><given-names>K</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><fpage>1286</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1470-z</pub-id><pub-id pub-id-type="pmid">19360396</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><name><surname>Michel</surname><given-names>F</given-names></name><name><surname>Thomachot</surname><given-names>L</given-names></name><name><surname>David</surname><given-names>M</given-names></name><name><surname>Nicaise</surname><given-names>C</given-names></name><name><surname>Vialet</surname><given-names>R</given-names></name><name><surname>Di Marco</surname><given-names>JN</given-names></name><name><surname>Lagier</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><article-title>Continuous low-dose infusion of terlipressin as a rescue therapy in meningococcal septic shock</article-title><source>Am J Emerg Med</source><year>2007</year><volume>25</volume><fpage>863.e1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2007.02.019</pub-id><pub-id pub-id-type="pmid">17870513</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Koehler</surname><given-names>G</given-names></name><name><surname>Broking</surname><given-names>K</given-names></name><name><surname>Hucklenbruch</surname><given-names>C</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Continuous versus bolus infusion of terlipressin in ovine endotoxemia</article-title><source>Shock</source><year>2007</year><volume>28</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">17589382</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><name><surname>Broking</surname><given-names>K</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Aken</surname><given-names>HV</given-names></name><name><surname>Luecke</surname><given-names>M</given-names></name><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Bowering</surname><given-names>N</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Employing dobutamine as a useful agent to reverse the terlipressin-linked impairments in cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep</article-title><source>Shock</source><year>2008</year><volume>29</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">17666952</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><name><surname>Ryckwaert</surname><given-names>F</given-names></name><name><surname>Virsolvy</surname><given-names>A</given-names></name><name><surname>Fort</surname><given-names>A</given-names></name><name><surname>Murat</surname><given-names>B</given-names></name><name><surname>Richard</surname><given-names>S</given-names></name><name><surname>Guillon</surname><given-names>G</given-names></name><name><surname>Colson</surname><given-names>PH</given-names></name><article-title>Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>876</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31819b8199</pub-id><pub-id pub-id-type="pmid">19237891</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><name><surname>Ouattara</surname><given-names>A</given-names></name><name><surname>Landi</surname><given-names>M</given-names></name><name><surname>Le Manach</surname><given-names>Y</given-names></name><name><surname>Lecomte</surname><given-names>P</given-names></name><name><surname>Leguen</surname><given-names>M</given-names></name><name><surname>Boccara</surname><given-names>G</given-names></name><name><surname>Coriat</surname><given-names>P</given-names></name><name><surname>Riou</surname><given-names>B</given-names></name><article-title>Comparative cardiac effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart</article-title><source>Anesthesiology</source><year>2005</year><volume>102</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1097/00000542-200501000-00016</pub-id><pub-id pub-id-type="pmid">15618791</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><name><surname>Noguera</surname><given-names>I</given-names></name><name><surname>Medina</surname><given-names>P</given-names></name><name><surname>Segarra</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>MC</given-names></name><name><surname>Aldasoro</surname><given-names>M</given-names></name><name><surname>Vila</surname><given-names>JM</given-names></name><name><surname>Lluch</surname><given-names>S</given-names></name><article-title>Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery</article-title><source>Br J Pharmacol</source><year>1997</year><volume>122</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0701397</pub-id><pub-id pub-id-type="pmid">9351498</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><name><surname>Urge</surname><given-names>J</given-names></name><name><surname>Sincl</surname><given-names>F</given-names></name><name><surname>Prochazka</surname><given-names>V</given-names></name><name><surname>Urbanek</surname><given-names>K</given-names></name><article-title>Terlipressin-induced ventricular arrhythmia</article-title><source>Scand J Gastroenterol</source><year>2008</year><volume>43</volume><fpage>1145</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1080/00365520801905304</pub-id><pub-id pub-id-type="pmid">18609153</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><name><surname>Siami</surname><given-names>S</given-names></name><name><surname>Bailly-Salin</surname><given-names>J</given-names></name><name><surname>Polito</surname><given-names>A</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Haymann</surname><given-names>JP</given-names></name><name><surname>Laborde</surname><given-names>K</given-names></name><name><surname>Maxime</surname><given-names>V</given-names></name><name><surname>Boucly</surname><given-names>C</given-names></name><name><surname>Carlier</surname><given-names>R</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name><article-title>Osmoregulation of vasopressin secretion is altered in the postacute phase of septic shock</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><fpage>1962</fpage><lpage>1969</lpage><pub-id pub-id-type="pmid">20639747</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><name><surname>Bauer</surname><given-names>SR</given-names></name><name><surname>Aloi</surname><given-names>JJ</given-names></name><name><surname>Ahrens</surname><given-names>CL</given-names></name><name><surname>Yeh</surname><given-names>JY</given-names></name><name><surname>Culver</surname><given-names>DA</given-names></name><name><surname>Reddy</surname><given-names>AJ</given-names></name><article-title>Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: a retrospective cohort study</article-title><source>J Crit Care</source><year>2010</year><volume>25</volume><fpage>362.e7</fpage><lpage>362.e11</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2009.10.005</pub-id><pub-id pub-id-type="pmid">19926252</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="other"><name><surname>Holt</surname><given-names>DB</given-names></name><name><surname>Delaney</surname><given-names>RR</given-names></name><name><surname>Uyehara</surname><given-names>CF</given-names></name><article-title>Effects of combination dobutamine and vasopressin therapy on microcirculatory blood flow in a porcine model of severe endotoxic shock</article-title><source>J Surg Res</source><year>2009</year><comment>[Epub ahead of print]</comment></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Spiegel</surname><given-names>HU</given-names></name><name><surname>K&#x000f6;hler</surname><given-names>G</given-names></name><name><surname>Erren</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Seisel</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><fpage>2016</fpage><lpage>2023</lpage><pub-id pub-id-type="pmid">20657271</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><name><surname>Nakada</surname><given-names>T</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Wellman</surname><given-names>H</given-names></name><name><surname>Boyd</surname><given-names>JH</given-names></name><name><surname>Nakada</surname><given-names>E</given-names></name><name><surname>Thain</surname><given-names>KR</given-names></name><name><surname>Thair</surname><given-names>SA</given-names></name><name><surname>Hirasawa</surname><given-names>H</given-names></name><name><surname>Oda</surname><given-names>S</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><article-title>Leucyl/cystinyl aminopeptidase (LNPEP) gene variants in septic shock</article-title><source>Chest</source><year>2011</year><volume>139</volume><fpage>1042</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1378/chest.10-2517</pub-id><pub-id pub-id-type="pmid">21330387</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="other"><name><surname>Wagener</surname><given-names>G</given-names></name><name><surname>Kovalevskaya</surname><given-names>G</given-names></name><name><surname>Minhaz</surname><given-names>M</given-names></name><name><surname>Mattis</surname><given-names>F</given-names></name><name><surname>Emond</surname><given-names>JC</given-names></name><name><surname>Landry</surname><given-names>DW</given-names></name><article-title>Vasopressin deficiency and vasodilatory state in end-stage liver disease</article-title><source>J Cardiothorac Vasc Anesth</source><year>2010</year><comment> in press </comment></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Whorton</surname><given-names>E</given-names></name><name><surname>D&#x000fc;nser</surname><given-names>M</given-names></name><name><surname>Strohh&#x000e4;cker</surname><given-names>AK</given-names></name><name><surname>Lipke</surname><given-names>E</given-names></name><name><surname>Kampmeier</surname><given-names>TG</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><fpage>R200</fpage><pub-id pub-id-type="doi">10.1186/cc9320</pub-id><pub-id pub-id-type="pmid">21054850</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Carlier</surname><given-names>R</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Feyde</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Paillard</surname><given-names>M</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Gajdos</surname><given-names>P</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><article-title>Depletion of neurohypophyseal content of vasopressin in septic shock</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1097/00003246-200203000-00001</pub-id><pub-id pub-id-type="pmid">11990905</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Paillard</surname><given-names>M</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Gajdos</surname><given-names>P</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><article-title>Circulating vasopressin levels in septic shock</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1752</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000063046.82359.4A</pub-id><pub-id pub-id-type="pmid">12794416</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><name><surname>Le Clerc</surname><given-names>F</given-names></name><name><surname>Walter-Nicolet</surname><given-names>E</given-names></name><name><surname>Leteurtre</surname><given-names>S</given-names></name><name><surname>Noizet</surname><given-names>O</given-names></name><name><surname>Sadik</surname><given-names>A</given-names></name><name><surname>Cremer</surname><given-names>R</given-names></name><name><surname>Fourier</surname><given-names>C</given-names></name><article-title>Admission plasma vasopressin levels in children with meningococcal septic shock</article-title><source>Intensive Care Med</source><year>2003</year><volume>29</volume><fpage>1339</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1007/s00134-003-1868-y</pub-id><pub-id pub-id-type="pmid">12856123</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><name><surname>Kruger</surname><given-names>S</given-names></name><name><surname>Ewig</surname><given-names>S</given-names></name><name><surname>Kunde</surname><given-names>J</given-names></name><article-title>C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia - influence of antibiotic pretreatment. Results from the German competence network (CAPNETZ)</article-title><source>J Antimicrob Chemother</source><year>2009</year><volume>64</volume><fpage>159</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1093/jac/dkp148</pub-id><pub-id pub-id-type="pmid">19403654</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><name><surname>de Kruif</surname><given-names>MD</given-names></name><name><surname>Lemaire</surname><given-names>LC</given-names></name><name><surname>Giebelen</surname><given-names>IA</given-names></name><name><surname>Struck</surname><given-names>J</given-names></name><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Papassotiriou</surname><given-names>J</given-names></name><name><surname>Elliott</surname><given-names>PJ</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name><article-title>The influence of corticosteroids on the release of novel biomarkers in human endotoxemia</article-title><source>Intensive Care Med</source><year>2008</year><volume>34</volume><fpage>518</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s00134-007-0955-x</pub-id><pub-id pub-id-type="pmid">18080111</pub-id></mixed-citation></ref></ref-list></back></article>